Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Aliment Pharmacol Ther

Retrieve available abstracts of 682 articles:
HTML format



Single Articles


    August 2021
  1. HONAP S, Pavlidis P, Irving PM
    Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?
    Aliment Pharmacol Ther. 2021;54:341-342.
    PubMed    


    July 2021
  2. VISURI I, Eriksson C, Olen O, Cao Y, et al
    Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register.
    Aliment Pharmacol Ther. 2021 Jul 19. doi: 10.1111/apt.16525.
    PubMed     Abstract available


  3. MCGING JJ, Radford SJ, Francis ST, Serres S, et al
    Review article: The aetiology of fatigue in inflammatory bowel disease and potential therapeutic management strategies.
    Aliment Pharmacol Ther. 2021 Jul 6. doi: 10.1111/apt.16465.
    PubMed     Abstract available


  4. LUBER RP, O'Neill R, Singh S, Sharma E, et al
    An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.
    Aliment Pharmacol Ther. 2021 Jul 5. doi: 10.1111/apt.16497.
    PubMed     Abstract available


  5. ROTONDO-TRIVETTE S, Wang B, Gayer C, Parsana R, et al
    Decreased secondary faecal bile acids in children with ulcerative colitis and Clostridioides difficile infection.
    Aliment Pharmacol Ther. 2021 Jul 4. doi: 10.1111/apt.16496.
    PubMed     Abstract available


  6. OSENI E, Sultan K
    Letter: opioid use, early biologic discontinuation for inflammatory bowel disease and a cautionary note for the age of legalised cannabis.
    Aliment Pharmacol Ther. 2021;54:92-93.
    PubMed    


  7. JORDI SBU, Misselwitz B, Begre S
    Editorial: type D personality and its relationship with depression and disease activity in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2021;54:82-83.
    PubMed    


  8. KNOWLES SR, Mikocka-Walus A
    Editorial: type D personality and its relationship with depression and disease activity in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021;54:80-81.
    PubMed    


  9. FAN D, Gearry RB
    Editorial: IBD medications during the COVID-19 pandemic-are they safe to use?
    Aliment Pharmacol Ther. 2021;54:208-209.
    PubMed    


  10. TASSONE D, Singh S, Sheng Ding N
    Editorial: impact of body mass index on clinical outcomes in patients with ulcerative colitis treated with tofacitinib.
    Aliment Pharmacol Ther. 2021;54:206-207.
    PubMed    


  11. MEYER A, Semenzato L, Zureik M, Weill A, et al
    Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study.
    Aliment Pharmacol Ther. 2021;54:160-166.
    PubMed     Abstract available


  12. CASANOVA MJ, Chaparro M, Gisbert JP
    Editorial: withdrawal of anti-TNFalpha-are we ready for biological therapy cycling? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:86-87.
    PubMed    


  13. PUGLIESE D, Armuzzi A
    Editorial: withdrawal of anti TNF-alpha - are we ready for biological therapy cycling?
    Aliment Pharmacol Ther. 2021;54:84-85.
    PubMed    


  14. WEISSHOF R, Chowers Y, Kurnik D
    Editorial: safety of thiopurines in pregnancy-considering the mother, foetus and newborn.
    Aliment Pharmacol Ther. 2021;54:88-89.
    PubMed    


    June 2021
  15. FARRAYE FA, Qazi T, Kotze PG, Moore GT, et al
    The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.
    Aliment Pharmacol Ther. 2021 Jun 24. doi: 10.1111/apt.16439.
    PubMed     Abstract available


  16. MEYER A, Drouin J, Weill A, Carbonnel F, et al
    Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018.
    Aliment Pharmacol Ther. 2021 Jun 23. doi: 10.1111/apt.16448.
    PubMed     Abstract available


  17. FRIEDMAN AB, Asthana A, Knowles SR, Robbins A, et al
    Effect of point-of-care gastrointestinal ultrasound on decision-making and management in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jun 22. doi: 10.1111/apt.16452.
    PubMed     Abstract available


  18. BERNSTEIN CN, Nugent Z, Shaffer S, Singh H, et al
    Comorbidity before and after a diagnosis of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jun 22. doi: 10.1111/apt.16444.
    PubMed     Abstract available


  19. UZZAN M, Bresteau C, Laharie D, Stefanescu C, et al
    Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort.
    Aliment Pharmacol Ther. 2021 Jun 20. doi: 10.1111/apt.16463.
    PubMed     Abstract available


  20. KO Y, Paramsothy S, Yau Y, Leong RW, et al
    Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Aliment Pharmacol Ther. 2021 Jun 20. doi: 10.1111/apt.16436.
    PubMed     Abstract available


  21. VAN LINSCHOTEN RCA, Visser E, Niehot CD, van der Woude CJ, et al
    Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.
    Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16445.
    PubMed     Abstract available


  22. FAIRBRASS KM, Gracie DJ, Ford AC
    Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16454.
    PubMed     Abstract available


  23. LAMB CA, Sebastian S, Kent AJ, Segal JP, et al
    Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.
    Aliment Pharmacol Ther. 2021;53:1236-1240.
    PubMed    


  24. EL-MATARY W, Nugent Z, Witt J, Bernstein CN, et al
    Editorial: trends in paediatric inflammatory bowel disease attributable direct costs-authors' reply.
    Aliment Pharmacol Ther. 2021;53:1234-1235.
    PubMed    


  25. VERNON-ROBERTS A, Day AS
    Editorial: trends in paediatric inflammatory bowel disease attributable direct costs.
    Aliment Pharmacol Ther. 2021;53:1232-1233.
    PubMed    


  26. TANNOURY J, Amiot A
    Editorial: determining disability in inflammatory bowel disease-"See(k) and you shall find". Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1323.
    PubMed    


  27. TURBAYNE AKB, Ward MG
    Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind.
    Aliment Pharmacol Ther. 2021;53:1317-1318.
    PubMed    


  28. ROBLIN X, Nancey S, Paul S
    Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1319-1320.
    PubMed    


  29. LIMDI JK
    Editorial: determining disability in IBD - 'See(k) and you shall find'.
    Aliment Pharmacol Ther. 2021;53:1321-1322.
    PubMed    


  30. MANLAY L, Boschetti G, Pereira B, Flourie B, et al
    Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
    Aliment Pharmacol Ther. 2021;53:1289-1299.
    PubMed     Abstract available


    May 2021
  31. JORDI SBU, Botte F, Lang BM, Greuter T, et al
    Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 May 11. doi: 10.1111/apt.16365.
    PubMed     Abstract available


  32. CASANOVA MJ, Chaparro M, Nantes O, Benitez JM, et al
    Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study.
    Aliment Pharmacol Ther. 2021 May 7. doi: 10.1111/apt.16361.
    PubMed     Abstract available


  33. SRINIVASAN A, Haifer C, Thin L
    Editorial: outcomes following a second switch-evaluating clinical outcomes and patient perspectives in IBD.
    Aliment Pharmacol Ther. 2021;53:1038-1039.
    PubMed    


  34. WILSON A, Kim RB
    Letter: genetic variation in the HLA-DQA1*05 allele predicts tumour necrosis factor-alpha antagonist immunogenicity - does location matter?
    Aliment Pharmacol Ther. 2021;53:1055-1056.
    PubMed    


  35. DEMARZO MG, Bodini G, Vanello M, Martini M, et al
    Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD.
    Aliment Pharmacol Ther. 2021;53:1044-1045.
    PubMed    


  36. RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
    Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1046-1047.
    PubMed    


  37. MESONERO F, Castro-Poceiro J, Benitez JM, Camps B, et al
    Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-alpha: results from the ENEIDA registry.
    Aliment Pharmacol Ther. 2021;53:1021-1029.
    PubMed     Abstract available


  38. SEDANO R, Ma C, Jairath V
    Editorial: standardising inclusion and outcome criteria for pouchitis-a fragile consensus perhaps but a first step in the right direction. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1149-1150.
    PubMed    


  39. LAUBE R, Selinger CP
    Editorial: standardising inclusion and outcome criteria for pouchitis-a fragile consensus perhaps but a first step in the right direction.
    Aliment Pharmacol Ther. 2021;53:1147-1148.
    PubMed    


  40. TANNOURY J, Nachury M, Martins C, Serrero M, et al
    Determinants of IBD-related disability: a cross-sectional survey from the GETAID.
    Aliment Pharmacol Ther. 2021;53:1098-1107.
    PubMed     Abstract available


  41. TJANDRA D, Garg M, Behrenbruch C, McCormick J, et al
    Review article: investigation and management of internal fistulae in Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:1064-1079.
    PubMed     Abstract available


    April 2021
  42. DHALIWAL J, McKay HE, Deslandres C, Debruyn J, et al
    One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
    Aliment Pharmacol Ther. 2021 Apr 28. doi: 10.1111/apt.16388.
    PubMed     Abstract available


  43. TOURNIER Q, Paul S, Williet N, Berger AE, et al
    Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Apr 19. doi: 10.1111/apt.16333.
    PubMed     Abstract available


  44. EL-MATARY W, Nugent Z, Witt J, Bernstein CN, et al
    Trends in paediatric inflammatory bowel disease-attributable direct costs: a population-based analysis.
    Aliment Pharmacol Ther. 2021 Apr 9. doi: 10.1111/apt.16358.
    PubMed     Abstract available


  45. VAN DER HAVE M, Maljaars J
    Editorial: opioids in inflammatory bowel disease-primum non nocere.
    Aliment Pharmacol Ther. 2021;53:844-845.
    PubMed    


  46. RHUDY C, Perry CL, Barrett TA
    Editorial: opioids in inflammatory bowel disease-primum non nocere. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:846.
    PubMed    


  47. JANGI S, Yoon H, Dulai P, Valasek M, et al
    Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis-authors' reply.
    Aliment Pharmacol Ther. 2021;53:957-958.
    PubMed    


  48. MAEDA Y, Kudo SE, Takishima K, Misawa M, et al
    Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis.
    Aliment Pharmacol Ther. 2021;53:955-956.
    PubMed    


  49. PRENTICE RE, Hollingsworth L, Middleton C, Wilson J, et al
    Letter: colorectal cancer surveillance in inflammatory bowel disease-a call for systematic reform.
    Aliment Pharmacol Ther. 2021;53:953-954.
    PubMed    


  50. LUBELL JM
    Letter: future studies of high-dose thiamine should consider whether its effects on fatigue are related to the inhibition of carbonic anhydrase isoenzymes.
    Aliment Pharmacol Ther. 2021;53:851-852.
    PubMed    


  51. BAGER P, Hvas C, Rud C, Dahlerup J, et al
    Letter: future studies of high-dose thiamine should consider whether its effects on fatigue are related to the inhibition of carbonic anhydrase isoenzymes. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:853-854.
    PubMed    


  52. LIM G, Kassam Z, Seow CH
    Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity?
    Aliment Pharmacol Ther. 2021;53:855-856.
    PubMed    


  53. TURSI A, Mocci G, Picchio M, Elisei W, et al
    Letter: ustekinumab for the treatment of post-surgical and refractory Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:859-860.
    PubMed    


  54. LAHARIE D, Riviere P
    Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:857-858.
    PubMed    


  55. ALMRADI A, Ma C, D'Haens GR, Sandborn WJ, et al
    An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials.
    Aliment Pharmacol Ther. 2021;53:784-793.
    PubMed     Abstract available


  56. ABUSHAMMA S, Deepak P
    Editorial: use of intestinal ultrasound in the scoring of Crohn's disease activity in clinical trials-is it ready for prime time yet?
    Aliment Pharmacol Ther. 2021;53:946-947.
    PubMed    


  57. JAIRATH V, Almradi A, Pai RK, Ma C, et al
    Editorial: an expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials-a missing link. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:952.
    PubMed    


  58. TANDON P, Narula N
    Editorial: methotrexate in patients with Crohn's disease refractory to anti-TNF therapy-moving backwards yet forward?
    Aliment Pharmacol Ther. 2021;53:950-951.
    PubMed    


  59. GOODSALL TM, Jairath V, Bryant RV, Ma C, et al
    Editorial: use of intestinal ultrasound in the scoring of Crohn's disease activity in clinical trials - is it ready for prime time yet? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:948-949.
    PubMed    


  60. GOODSALL TM, Jairath V, Feagan BG, Parker CE, et al
    Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:873-886.
    PubMed     Abstract available


    March 2021
  61. WORLEY G, Faiz O
    Editorial: time trends in colectomy rates for ulcerative colitis in England-mixed methods brings mixed messages? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:661-662.
    PubMed    


  62. BODGER K
    Editorial: time trends in colectomy rates for ulcerative colitis in England-mixed methods brings mixed messages?
    Aliment Pharmacol Ther. 2021;53:660.
    PubMed    


  63. LAHARIE D
    Editorial: is enteral nutrition back in acute severe ulcerative colitis?
    Aliment Pharmacol Ther. 2021;53:745-746.
    PubMed    


  64. AL-ANI AH, Prentice RE, Rentsch C, Christensen B, et al
    Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply.
    Aliment Pharmacol Ther. 2021;53:766-767.
    PubMed    


  65. SAHU P, Kedia S, Kumar Vuyyuru S, Travis S, et al
    Editorial: is enteral nutrition back in acute severe ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:747-748.
    PubMed    


  66. O'MORAIN N, Coe C, Mallon P, Twomey P, et al
    Letter: how frequently does COVID-19 mimic an IBD flare when community transmission of SARS-CoV-2 is active?
    Aliment Pharmacol Ther. 2021;53:674-675.
    PubMed    


  67. PRIVITERA G, Pugliese D, Scaldaferri F, Armuzzi A, et al
    Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy.
    Aliment Pharmacol Ther. 2021;53:764-765.
    PubMed    


  68. TRYSTRAM N, Abitbol V, Tannoury J, Lecomte M, et al
    Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
    Aliment Pharmacol Ther. 2021 Mar 1. doi: 10.1111/apt.16312.
    PubMed     Abstract available


  69. KANESHIRO M, Takenaka K, Suzuki K, Fujii T, et al
    Pancolonic endoscopic and histologic evaluation for relapse prediction in patients with ulcerative colitis in clinical remission.
    Aliment Pharmacol Ther. 2021 Mar 1. doi: 10.1111/apt.16310.
    PubMed     Abstract available


  70. MANTZARIS GJ, Bamias G
    Editorial: an expert consensus to standardise the assessment of histologic disease activity in Crohn's disease clinical trials-a missing link.
    Aliment Pharmacol Ther. 2021;53:749-750.
    PubMed    


  71. ROBLIN X, Paul S, Nancey S
    Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game.
    Aliment Pharmacol Ther. 2021;53:640-641.
    PubMed    


  72. RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
    Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply.
    Aliment Pharmacol Ther. 2021;53:642-643.
    PubMed    


  73. MCCURDY J, Boet S, Rosenfeld G
    Editorial: is hyperbaric oxygen a therapeutic opportunity for refractory perianal Crohn's disease?
    Aliment Pharmacol Ther. 2021;53:667-668.
    PubMed    


  74. LAFEUILLE P, Hordonneau C, Vignette J, Blayac L, et al
    Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:577-586.
    PubMed     Abstract available


  75. LANSDORP CA, Gecse KB, Buskens CJ, Lowenberg M, et al
    Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:587-597.
    PubMed     Abstract available


    February 2021
  76. FLANAGAN E, Wright EK, Hardikar W, Sparrow MP, et al
    Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates.
    Aliment Pharmacol Ther. 2021 Feb 19. doi: 10.1111/apt.16294.
    PubMed     Abstract available


  77. JAHRAUS CD
    Editorial: "Please Sir, I want some more" data to guide delivery of abdominopelvic radiotherapy in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021;53:454-455.
    PubMed    


  78. AXELRAD JE
    Editorial: immune-mediated diseases-are we closer to disease-defining molecular signatures?
    Aliment Pharmacol Ther. 2021;53:563-564.
    PubMed    


  79. DANESE S, Subramaniam K, Van Zyl J, Adsul S, et al
    Editorial: vedolizumab in inflammatory bowel diseases-less is more? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:445-446.
    PubMed    


  80. WILS P, Pariente B
    Editorial: keep calm and carry on-managing non-TNF antagonist biologics in pregnancy-authors' reply.
    Aliment Pharmacol Ther. 2021;53:452-453.
    PubMed    


  81. SEOW CH, Ma C
    Keep calm and carry on-managing non-TNF antagonist biologics in pregnancy.
    Aliment Pharmacol Ther. 2021;53:450-451.
    PubMed    


  82. TOWNSEND T, Subramanian S
    Editorial: vedolizumab in inflammatory bowel diseases-less is more?
    Aliment Pharmacol Ther. 2021;53:443-444.
    PubMed    


  83. MESERVE J, Facciorusso A, Holmer AK, Annese V, et al
    Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2021;53:374-382.
    PubMed     Abstract available


    January 2021
  84. RHUDY C, Perry CL, Singleton M, Talbert J, et al
    Chronic opioid use is associated with early biologic discontinuation in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jan 26. doi: 10.1111/apt.16269.
    PubMed     Abstract available


  85. SAHU P, Kedia S, Vuyyuru SK, Bajaj A, et al
    Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2021 Jan 13. doi: 10.1111/apt.16249.
    PubMed     Abstract available


  86. CHEE D, Kennedy NA, Goodhand JR, Ahmad T, et al
    Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the root. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:337-338.
    PubMed    


  87. MAHMOUD R, Itzkowitz SH
    Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the root.
    Aliment Pharmacol Ther. 2021;53:335-336.
    PubMed    


  88. LORD A, Radford-Smith G
    Letter: hidden costs in healthcare use for incident and prevalent Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2021;53:368-369.
    PubMed    


  89. RIMOLA J, Panes J, Ordas I
    Letter: accuracy of magnetic resonance index of activity score to predict response to biologics in Crohn's disease-authors' reply.
    Aliment Pharmacol Ther. 2021;53:207-208.
    PubMed    


  90. DEBNATH P, Rathi P
    Letter: accuracy of magnetic resonance index of activity score to predict response to biologics in Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:205-206.
    PubMed    


  91. MURRAY CD
    Editorial: fatigue-difficult to assess and difficult to treat.
    Aliment Pharmacol Ther. 2021;53:339.
    PubMed    


  92. LEBLANC JF, Hart AL
    Editorial: a pipe dream fulfilled? A therapeutic option for fatigue in IBD.
    Aliment Pharmacol Ther. 2021;53:342-343.
    PubMed    


  93. TOWNSEND T, Subramanian S
    Letter: propensity score-handle with care. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:362-363.
    PubMed    


  94. MACALUSO FS, Orlando A
    Letter: propensity score-handle with care.
    Aliment Pharmacol Ther. 2021;53:360-361.
    PubMed    


  95. CARBERY I, Selinger CP
    Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD?
    Aliment Pharmacol Ther. 2021;53:346-347.
    PubMed    


  96. BAGER P, Hvas CL, Rud CL, Dahlerup JF, et al
    Editorial: a pipe dream fulfilled? A therapeutic option for fatigue in IBD. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:344-345.
    PubMed    


  97. SCHREINER P, von Kanel R, Misselwitz B
    Editorial: fatigue-difficult to assess and difficult to treat. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:340-341.
    PubMed    


  98. BERTANI L, Pugliese D, Trico D, Costa F, et al
    Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:348-349.
    PubMed    


  99. NICE R, Chanchlani N, Green H, Bewshea C, et al
    Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays.
    Aliment Pharmacol Ther. 2021;53:128-137.
    PubMed     Abstract available


  100. DANESE S, Subramaniam K, Van Zyl J, Adsul S, et al
    Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.
    Aliment Pharmacol Ther. 2021;53:265-272.
    PubMed     Abstract available


  101. BERTANI L, Trico D, Pugliese D, Privitera G, et al
    Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients.
    Aliment Pharmacol Ther. 2021;53:273-280.
    PubMed     Abstract available


  102. FRAZZONI L, La Marca M, Radaelli F, Spada C, et al
    Systematic review with meta-analysis: the appropriateness of colonoscopy increases the probability of relevant findings and cancer while reducing unnecessary exams.
    Aliment Pharmacol Ther. 2021;53:22-32.
    PubMed     Abstract available


  103. PAI RK, Pai RK, Brown I, Choi WT, et al
    The significance of histological activity measurements in immune checkpoint inhibitor colitis.
    Aliment Pharmacol Ther. 2021;53:150-159.
    PubMed     Abstract available


  104. UNGARO RC, Hu L, Ji J, Nayar S, et al
    Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:281-290.
    PubMed     Abstract available


  105. KING D, Coupland B, Dosanjh A, Cole A, et al
    The risk of later surgery at the anastomotic site following right hemicolectomy for Crohn's disease in a national cohort of 12 230 patients.
    Aliment Pharmacol Ther. 2021;53:114-127.
    PubMed     Abstract available


    December 2020
  106. RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
    Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.
    Aliment Pharmacol Ther. 2020 Dec 19. doi: 10.1111/apt.16193.
    PubMed     Abstract available


  107. YE L, Chapman TP, Wen Z, Lin L, et al
    Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region.
    Aliment Pharmacol Ther. 2020 Dec 12. doi: 10.1111/apt.16130.
    PubMed     Abstract available


  108. PIOVANI D, Pansieri C, Peyrin-Biroulet L, Danese S, et al
    Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study.
    Aliment Pharmacol Ther. 2020 Dec 9. doi: 10.1111/apt.16222.
    PubMed     Abstract available


  109. WILS P, Seksik P, Stefanescu C, Nancey S, et al
    Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
    Aliment Pharmacol Ther. 2020 Dec 7. doi: 10.1111/apt.16192.
    PubMed     Abstract available


  110. LO CH, Khalili H, Lochhead P, Song M, et al
    Immune-mediated diseases and risk of Crohn's disease or ulcerative colitis: a prospective cohort study.
    Aliment Pharmacol Ther. 2020 Dec 5. doi: 10.1111/apt.16210.
    PubMed     Abstract available


  111. WORLEY G, Almoudaris A, Bassett P, Segal J, et al
    Colectomy rates for ulcerative colitis in England 2003-2016.
    Aliment Pharmacol Ther. 2020 Dec 2. doi: 10.1111/apt.16202.
    PubMed     Abstract available


  112. REUKEN PA, Wust M, Loffler B, Bauer M, et al
    Letter: SARS-CoV-2-induced gastrointestinal inflammation.
    Aliment Pharmacol Ther. 2020;52.
    PubMed    


    November 2020
  113. DOHOS D, Hanak L, Szakacs Z, Kiss S, et al
    Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Nov 28. doi: 10.1111/apt.16182.
    PubMed     Abstract available


  114. BROUSSARD D, Riviere P, Bonnet J, Fotsing G, et al
    Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID.
    Aliment Pharmacol Ther. 2020 Nov 26. doi: 10.1111/apt.16176.
    PubMed     Abstract available


  115. BAGER P, Hvas CL, Rud CL, Dahlerup JF, et al
    Randomised clinical trial: high-dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Nov 18. doi: 10.1111/apt.16166.
    PubMed     Abstract available


  116. HIBIYA S, Matsuyama Y, Fujii T, Maeyashiki C, et al
    5-aminosalicylate-intolerant patients are at increased risk of colectomy for ulcerative colitis.
    Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16120.
    PubMed     Abstract available


  117. SCHREINER P, Rossel JB, Biedermann L, Valko PO, et al
    Fatigue in inflammatory bowel disease and its impact on daily activities.
    Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16145.
    PubMed     Abstract available


  118. GORDON C, Chee D, Hamilton B, Heerasing NM, et al
    Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16155.
    PubMed     Abstract available


  119. MEYER A, Drouin J, Weill A, Carbonnel F, et al
    Pregnancy in women with inflammatory bowel disease: a French nationwide study 2010-2018.
    Aliment Pharmacol Ther. 2020;52:1480-1490.
    PubMed     Abstract available


  120. NICOLAIDES S, Vasudevan A, van Langenberg D
    Letter: rationalising aminosalicylates in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020;52:1619-1620.
    PubMed    


  121. MA C, Singh S, Heatherington J, Panaccione R, et al
    Editorial: is age just a number when it comes to treatment of inflammatory bowel disease?
    Aliment Pharmacol Ther. 2020;52:1615-1616.
    PubMed    


  122. ASSCHER VER, Biemans VBC, Hoentjen F, Maljaars PWJ, et al
    Editorial: is age just a number when it comes to treatment of inflammatory bowel disease? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1617-1618.
    PubMed    


  123. CHAPMAN TP, Frias Gomes C, Louis E, Colombel JF, et al
    Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2020;52:1621.
    PubMed    


  124. NARULA N, Aruljothy A, Alshahrani AA, Fadida M, et al
    Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission.
    Aliment Pharmacol Ther. 2020 Nov 1. doi: 10.1111/apt.16147.
    PubMed     Abstract available


  125. VASUDEVAN A, Con D, Nicolaides S, van Langenberg DR, et al
    Editorial: methotrexate vs azathioprine-do differential rates of discontinuation settle the debate? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1529-1530.
    PubMed    


  126. ZULFIQAR M, Deepak P
    Editorial: crystal gazing with magnetic resonance enterography to predict the response to TNF-alpha inhibitors in Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1531-1532.
    PubMed    


  127. FRASER AG
    Methotrexate or azathioprine-do differing rates of discontinuation settle the debate?
    Aliment Pharmacol Ther. 2020;52:1527-1528.
    PubMed    


  128. FLANAGAN E, Gibson PR, Wright EK, Moore GT, et al
    Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
    Aliment Pharmacol Ther. 2020;52:1551-1562.
    PubMed     Abstract available


  129. TAYLOR H, Serrano-Contreras JI, McDonald JAK, Epstein J, et al
    Multiomic features associated with mucosal healing and inflammation in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1491-1502.
    PubMed     Abstract available


  130. RIMOLA J, Fernandez-Clotet A, Capozzi N, Rojas-Farreras S, et al
    Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1563-1573.
    PubMed     Abstract available


    October 2020
  131. BANERJEE R, Ravikanth VV, Pal P, Bale G, et al
    NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine-induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India.
    Aliment Pharmacol Ther. 2020 Oct 27. doi: 10.1111/apt.16137.
    PubMed     Abstract available


  132. PANACCIONE R, Danese S, Sandborn WJ, O'Brien CD, et al
    Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
    Aliment Pharmacol Ther. 2020 Oct 21. doi: 10.1111/apt.16119.
    PubMed     Abstract available


  133. AMIOT A, Salameh R
    Letter: long-term outcomes of patients with acute severe ulcerative colitis after intravenous steroid therapy-authors' reply.
    Aliment Pharmacol Ther. 2020;52:1252.
    PubMed    


  134. FABIAN A, Bor R, Farkas K, Szepes Z, et al
    Letter: long-term outcomes of patients with acute severe ulcerative colitis after intravenous steroid therapy.
    Aliment Pharmacol Ther. 2020;52:1251.
    PubMed    


  135. PRENTICE RE, Tjandra D, Garg M, Lubel JS, et al
    Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19.
    Aliment Pharmacol Ther. 2020;52:1422-1423.
    PubMed    


  136. BRITTON E, Richardson P, Mian I, Conley T, et al
    Letter: Covid-19-re-initiating clinical services for chronic gastrointestinal diseases. How and when?
    Aliment Pharmacol Ther. 2020;52:1414-1415.
    PubMed    


  137. BIEMANS VBC, Hoentjen F, Pierik MJ
    Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1255-1256.
    PubMed    


  138. LIU K, Cai F, Huang J
    Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth?
    Aliment Pharmacol Ther. 2020;52:1253-1254.
    PubMed    


  139. LAHARIE D, Riviere P
    Editorial: biologics in the therapy of Crohn's disease-the fog clears.
    Aliment Pharmacol Ther. 2020;52:1214-1215.
    PubMed    


  140. MERTZ NORGARD B, Friedman S
    Editorial: thiopurine/anti-TNF use during pregnancy-more encouraging safety data. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1411.
    PubMed    


  141. BETTENWORTH D, Bokemeyer A, Kou L, Lopez R, et al
    Systematic review with meta-analysis: efficacy of balloon-assisted enteroscopy for dilation of small bowel Crohn's disease strictures.
    Aliment Pharmacol Ther. 2020;52:1104-1116.
    PubMed     Abstract available


  142. TOWNSEND T, Razanskaite V, Dodd S, Storey D, et al
    Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1341-1352.
    PubMed     Abstract available


    September 2020
  143. BATTAT R, Vande Casteele N, Pai RK, Wang Z, et al
    Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study.
    Aliment Pharmacol Ther. 2020 Sep 27. doi: 10.1111/apt.16083.
    PubMed     Abstract available


  144. CAENEPEEL C, Sadat Seyed Tabib N, Vieira-Silva S, Vermeire S, et al
    Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Sep 24. doi: 10.1111/apt.16096.
    PubMed     Abstract available


  145. ASSCHER VER, Biemans VBC, Pierik MJ, Dijkstra G, et al
    Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study.
    Aliment Pharmacol Ther. 2020 Sep 9. doi: 10.1111/apt.16073.
    PubMed     Abstract available


  146. LOFTUS EV JR, Feagan BG, Panaccione R, Colombel JF, et al
    Long-term safety of vedolizumab for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Sep 2. doi: 10.1111/apt.16060.
    PubMed     Abstract available


  147. VASUDEVAN A, van Langenberg DR
    Editorial: direct costs are only the tip of the iceberg in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020;52:879-880.
    PubMed    


  148. LOVATT J, Selinger CP
    Letter: recognising frailty in patients with inflammatory bowel disease is crucial for appropriate personalised treatment.
    Aliment Pharmacol Ther. 2020;52:908-909.
    PubMed    


  149. QURAISHI MN, Segal JP, Cooney R, Kennedy NA, et al
    Letter: online search trends suggest patient concerns around immunosuppression use in inflammatory bowel disease during COVID-19 in the United Kingdom.
    Aliment Pharmacol Ther. 2020;52:937-939.
    PubMed    


  150. JANGI S, Yoon H, Dulai PS, Valasek M, et al
    Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing.
    Aliment Pharmacol Ther. 2020;52:1008-1016.
    PubMed     Abstract available


  151. CHEE D, Goodhand JR, Ahmad T
    Editorial: is pharmacogenetic testing for adverse effects to IBD treatments ready for roll-out?
    Aliment Pharmacol Ther. 2020;52:1076-1077.
    PubMed    


  152. APPLETON L, Day AS
    Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
    Aliment Pharmacol Ther. 2020;52:1080-1081.
    PubMed    


  153. ROBLIN X, Le Roy B, Paul S
    Editorial: therapeutic drug monitoring for golimumab - ready for prime time?
    Aliment Pharmacol Ther. 2020;52:1078-1079.
    PubMed    


  154. BERTANI L, Fornai M, Antonioli L, Blandizzi C, et al
    Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab-authors' reply.
    Aliment Pharmacol Ther. 2020;52:1082.
    PubMed    


  155. KOPYLOV U
    Letter: optimising response to ustekinumab therapy for patients with Crohn's disease-author's reply.
    Aliment Pharmacol Ther. 2020;52:907.
    PubMed    


  156. DESAI D, Abraham P
    Letter: monitoring interval for thiopurine therapy - a comment.
    Aliment Pharmacol Ther. 2020;52:910.
    PubMed    


  157. HUDSON J, Herfarth HH, Barnes EL
    Letter: optimising response to ustekinumab therapy for patients with Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:906.
    PubMed    


  158. JONES K, Baker K, Speight RA, Thompson NP, et al
    Randomised clinical trial: combined impact and resistance training in adults with stable Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:964-975.
    PubMed     Abstract available


  159. BROMS G, Kieler H, Ekbom A, Gissler M, et al
    Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy.
    Aliment Pharmacol Ther. 2020;52:843-854.
    PubMed     Abstract available


  160. IBORRA M, Beltran B, Fernandez-Clotet A, Iglesias-Flores E, et al
    Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry.
    Aliment Pharmacol Ther. 2020;52:1017-1030.
    PubMed     Abstract available


    August 2020
  161. CHUPIN A, Perduca V, Meyer A, Bellanger C, et al
    Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Aug 25. doi: 10.1111/apt.16050.
    PubMed     Abstract available


  162. VASUDEVAN A, Parthasarathy N, Con D, Nicolaides S, et al
    Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Aug 14. doi: 10.1111/apt.16039.
    PubMed     Abstract available


  163. DULAI PS, Raffals LE, Hudesman D, Chiorean M, et al
    A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares.
    Aliment Pharmacol Ther. 2020 Aug 3. doi: 10.1111/apt.15984.
    PubMed     Abstract available


  164. RESAL T, Pigniczki D, Szanto K, Rutka M, et al
    Letter: ciclosporin and vedolizumab for steroid-refractory ulcerative colitis.
    Aliment Pharmacol Ther. 2020;52:578-579.
    PubMed    


  165. GARG M, Royce SG, Lubel JS
    Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors.
    Aliment Pharmacol Ther. 2020;52:569-570.
    PubMed    


  166. YANG E, Panaccione N, Whitmire N, Dulai PS, et al
    Letter: combination of biologics in inflammatory bowel diseases. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:568-569.
    PubMed    


  167. KOPYLOV U
    Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval? Author's reply.
    Aliment Pharmacol Ther. 2020;52:565-566.
    PubMed    


  168. HRON BM, Cohen RD, Johnson SJ, Skup M, et al
    Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings?
    Aliment Pharmacol Ther. 2020;52:559-560.
    PubMed    


  169. SRINIVASAN A, De Cruz P, van Langenberg DR
    Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval?
    Aliment Pharmacol Ther. 2020;52:564-565.
    PubMed    


  170. MOURATIDOU N, Malmborg P, Olen O
    Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:560-561.
    PubMed    


  171. ALRIC H, Amiot A, Carbonnel F, Meyer A, et al
    Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:563-564.
    PubMed    


  172. K HOLMER A, Singh S
    Editorial: pancreatic cancer risk in inflammatory bowel diseases-it's all relative.
    Aliment Pharmacol Ther. 2020;52:550-551.
    PubMed    


  173. SRINIVASAN A, De Cruz P, van Langenberg DR
    Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail.
    Aliment Pharmacol Ther. 2020;52:561-562.
    PubMed    


  174. FUMERY M, Yzet C, Brazier F
    Letter: combination of biologics in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2020;52:566-567.
    PubMed    


  175. KHALILI H, Everhov AH, Halfvarson J, Ludvigsson JF, et al
    Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden.
    Aliment Pharmacol Ther. 2020;52:655-668.
    PubMed     Abstract available


  176. TAXONERA C, Alba C
    Editorial: social distancing during the COVID-19 pandemic-IBD patients cannot stay at home forever. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:719-720.
    PubMed    


  177. BENSON-POPE SJ, Gearry RB
    Editorial: social distancing during the COVID-19 pandemic - IBD patients cannot stay at home forever.
    Aliment Pharmacol Ther. 2020;52:717-718.
    PubMed    


  178. KHAN MU, Mushtaq K, Al-Ejji KMAA, Yakoob RA, et al
    Letter: IBD nurse-a pivotal role in the time of the pandemic.
    Aliment Pharmacol Ther. 2020;52:745.
    PubMed    


  179. BERTANI L, Antonioli L, Blandizzi C
    Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers?
    Aliment Pharmacol Ther. 2020;52:751-752.
    PubMed    


  180. AL-ANI AH, Rentsch CA, Azim S, Bidgood E, et al
    Letter: IBD nurse-pivotal role in the time of the pandemic. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:746-747.
    PubMed    


  181. BIEMANS VBC, Hoentjen F, Pierik MJ
    Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:753-754.
    PubMed    


  182. MARSH A, Radford-Smith G
    Editorial: obesity management and IBD-weight loss reduces IBD risk.
    Aliment Pharmacol Ther. 2020;52:731-732.
    PubMed    


  183. KANG B, Kim TJ, Choi J, Baek SY, et al
    Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers.
    Aliment Pharmacol Ther. 2020;52:459-470.
    PubMed     Abstract available


  184. WALKER GJ, Lin S, Chanchlani N, Thomas A, et al
    Quality improvement project identifies factors associated with delay in IBD diagnosis.
    Aliment Pharmacol Ther. 2020;52:471-480.
    PubMed     Abstract available


  185. BOHM M, Xu R, Zhang Y, Varma S, et al
    Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:669-681.
    PubMed     Abstract available


  186. SEGAL JP, Smith PJ
    Editorial: quality improvement project to identify factors associated with a delay in IBD diagnosis.
    Aliment Pharmacol Ther. 2020;52:733-734.
    PubMed    


    July 2020
  187. LANSDORP CA, Buskens CJ, Gecse KB, D'Haens GRAM, et al
    Letter: off-label use of hyperbaric oxygen therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020;52:215-216.
    PubMed    


  188. SIMSEK M, de Boer NKH
    Letter: off-label use of hyperbaric oxygen therapy in inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2020;52:216-217.
    PubMed    


  189. DETLIE TE, Jahnsen J
    Editorial: improving precision of iron deficiency diagnosis in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020;52:400.
    PubMed    


  190. DEEPAK P, Itani M
    Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitis-one more arrow in the quiver of non-invasive diagnostics.
    Aliment Pharmacol Ther. 2020;52:401-402.
    PubMed    


  191. SAGAMI S, Kobayashi T, Hibi T
    Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitis-one more arrow in the quiver of non-invasive diagnostics. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:403.
    PubMed    


  192. DAUDE S, Gastin I, Peyrin-Biroulet L
    Editorial: diagnostic precision of iron deficiency in inflammatory bowel disease. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:401.
    PubMed    


  193. TAXONERA C, Sagastagoitia I, Alba C, Manas N, et al
    2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2020;52:276-283.
    PubMed     Abstract available


  194. ABDEL-DAIM MM
    Editorial: the road to elimination of viral hepatitis-another promising real-world experience.
    Aliment Pharmacol Ther. 2020;52:405-406.
    PubMed    


  195. GARG M, Chand S, Weenink P, Yunqiu Wu K, et al
    Letter: assessing iron deficiency in patients with IBD-a step in the right direction, but uncertainty remains.
    Aliment Pharmacol Ther. 2020;52:413-415.
    PubMed    


  196. TOWNSEND T, Probert C
    Editorial: peristomal pyoderma gangrenosum-a challenge for patients, healthcare professionals and research.
    Aliment Pharmacol Ther. 2020;52:404-405.
    PubMed    


  197. BIEMANS VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, et al
    Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
    Aliment Pharmacol Ther. 2020;52:123-134.
    PubMed     Abstract available


  198. KABIR M, Fofaria R, Arebi N, Bassett P, et al
    Systematic review with meta-analysis: IBD-associated colonic dysplasia prognosis in the videoendoscopic era (1990 to present).
    Aliment Pharmacol Ther. 2020;52:5-19.
    PubMed     Abstract available


  199. KOPYLOV U, Hanzel J, Liefferinckx C, De Marco D, et al
    Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.
    Aliment Pharmacol Ther. 2020;52:135-142.
    PubMed     Abstract available


  200. KOCHAR B, Cai W, Cagan A, Ananthakrishnan AN, et al
    Frailty is independently associated with mortality in 11 001 patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2020;52:311-318.
    PubMed     Abstract available


  201. THOMANN AK, Mak JWY, Zhang JW, Wuestenberg T, et al
    Review article: bugs, inflammation and mood-a microbiota-based approach to psychiatric symptoms in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2020;52:247-266.
    PubMed     Abstract available


  202. DUMONT LM, Landman C, Sokol H, Beaugerie L, et al
    Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study.
    Aliment Pharmacol Ther. 2020;52:303-310.
    PubMed     Abstract available


  203. BERTANI L, Fornai M, Fornili M, Antonioli L, et al
    Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
    Aliment Pharmacol Ther. 2020;52:284-291.
    PubMed     Abstract available


    June 2020
  204. SINGH S, Kim J, Zhu W, Dulai PS, et al
    No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy.
    Aliment Pharmacol Ther. 2020 Jun 23. doi: 10.1111/apt.15876.
    PubMed     Abstract available


  205. SAMAAN MA, Cunningham G, Tamilarasan AG, Beltran L, et al
    Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study.
    Aliment Pharmacol Ther. 2020 Jun 7. doi: 10.1111/apt.15808.
    PubMed     Abstract available


  206. ALBSHESH A, Ben-Horin S
    Editorial: which biologic is next for ulcerative colitis patients who fail a subcutaneous anti-TNF?
    Aliment Pharmacol Ther. 2020;51:1198-1199.
    PubMed    


  207. SANDBORN WJ, Panes J, Sands BE, Reinisch W, et al
    Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:1209-1210.
    PubMed    


  208. SANTA A, Szanto KJ, Sarlos P, Miheller P, et al
    Letter: suicide risk among adult inflammatory bowel disease patients.
    Aliment Pharmacol Ther. 2020;51:1213-1214.
    PubMed    


  209. KOTZE PG, Teixeira FV, Damiao AOMC
    Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice.
    Aliment Pharmacol Ther. 2020;51:1208-1209.
    PubMed    


  210. MALHAM M, Jakobsen C, Paerregaard A, Hald M, et al
    Letter: suicide risk among adult inflammatory bowel disease patients. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:1214-1215.
    PubMed    


  211. LI WAI SUEN CFD, Choy MC, De Cruz P
    Letter: how can we reduce mortality in elderly patients with acute severe ulcerative colitis?
    Aliment Pharmacol Ther. 2020;51:1444-1445.
    PubMed    


  212. DONG C, Metzger M, Holsbo EE, Perduca V, et al
    Letter: how can we reduce mortality in elderly patients with acute severe ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:1445-1446.
    PubMed    


  213. BENSON-POPE SJ, Gearry RB
    Editorial: increasing IBD prevalence and its complications in the context of the COVID-19 pandemic.
    Aliment Pharmacol Ther. 2020;51:1441-1442.
    PubMed    


  214. KING DS, Trudgill NJ, Adderley NJ
    Editorial: increasing IBD prevalence and its complications in the context of the COVID-19 pandemic. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:1442-1443.
    PubMed    


  215. RHODES JM, Subramanian S, Laird E, Kenny RA, et al
    Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity.
    Aliment Pharmacol Ther. 2020;51:1434-1437.
    PubMed    


  216. CREEMERS RH, Bloem S, van Bodegraven AA
    Editorial: the most commonly used IBD indices still fail to represent real life and subjective patient experience.
    Aliment Pharmacol Ther. 2020;51:1202-1203.
    PubMed    


  217. PARIENTE B
    Editorial: the most commonly used IBD indices still fail to represent real life and subjective patient experience. Author's reply.
    Aliment Pharmacol Ther. 2020;51:1203-1204.
    PubMed    


  218. SCRIVO B, Renna S, Casa A, Monachino N, et al
    Letter: mesalazine-a safe drug with rare serious adverse events.
    Aliment Pharmacol Ther. 2020;51:1210-1211.
    PubMed    


  219. SEHGAL P, Narula N
    Letter: mesalazine-a safe drug with rare serious adverse events? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:1212.
    PubMed    


  220. MICELI MC, Arcuri C, Renna S, Orlando A, et al
    Letter: golimumab efficacy in patients with Crohn's disease and concomitant severe arthritis.
    Aliment Pharmacol Ther. 2020;51:1449-1451.
    PubMed    


  221. YANG E, Panaccione N, Whitmire N, Dulai PS, et al
    Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:1031-1038.
    PubMed     Abstract available


  222. LU C, Baraty B, Lee Robertson H, Filyk A, et al
    Systematic review: medical therapy for fibrostenosing Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:1233-1246.
    PubMed     Abstract available


  223. SRINIVASAN A, van Langenberg DR, Little RD, Sparrow MP, et al
    A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:1342-1352.
    PubMed     Abstract available


  224. PAPOUTSOPOULOU S, Satsangi J, Campbell BJ, Probert CS, et al
    Review article: impact of cigarette smoking on intestinal inflammation-direct and indirect mechanisms.
    Aliment Pharmacol Ther. 2020;51:1268-1285.
    PubMed     Abstract available


  225. CZAJA AJ
    Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis.
    Aliment Pharmacol Ther. 2020;51:1286-1304.
    PubMed     Abstract available


    May 2020
  226. CHAPMAN TP, Frias Gomes C, Louis E, Colombel JF, et al
    Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 May 26. doi: 10.1111/apt.15771.
    PubMed     Abstract available


  227. SHAH A, Talley NJ, Koloski N, Macdonald GA, et al
    Duodenal bacterial load as determined by quantitative polymerase chain reaction in asymptomatic controls, functional gastrointestinal disorders and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 May 15. doi: 10.1111/apt.15786.
    PubMed     Abstract available


  228. EVERHOV AH, Erichsen R, Sachs MC, Pedersen L, et al
    Inflammatory bowel disease and pancreatic cancer: a Scandinavian register-based cohort study 1969-2017.
    Aliment Pharmacol Ther. 2020 May 15. doi: 10.1111/apt.15785.
    PubMed     Abstract available


  229. WANG J, Prenner J, Wang W, Sakuraba A, et al
    Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 May 7. doi: 10.1111/apt.15766.
    PubMed     Abstract available


  230. SAGAMI S, Kobayashi T, Aihara K, Umeda M, et al
    Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis.
    Aliment Pharmacol Ther. 2020 May 7. doi: 10.1111/apt.15767.
    PubMed     Abstract available


  231. AXELRAD JE, Cadwell KH, Colombel JF, Shah SC, et al
    Systematic review: gastrointestinal infection and incident inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 May 5. doi: 10.1111/apt.15770.
    PubMed     Abstract available


  232. BANGMA A, Voskuil MD, Uniken Venema WTC, Brugge H, et al
    Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 May 3. doi: 10.1111/apt.15762.
    PubMed     Abstract available


  233. SANDS BE, Armuzzi A, Marshall JK, Lindsay JO, et al
    Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:997-998.
    PubMed    


  234. PENG C, Jiexin L, Yue W, Benhong Z, et al
    Letter: corticosteroid use alongside tofacitinib in OCTAVE Open.
    Aliment Pharmacol Ther. 2020;51:996-997.
    PubMed    


  235. LAUBE R, Selinger CP
    Letter: pregnant women with IBD are more likely to be adherent to biologic therapies than other medications.
    Aliment Pharmacol Ther. 2020;51:915-916.
    PubMed    


  236. LEE S, Seow CH, Adhikari K, Metcalfe A, et al
    Letter: pregnant women with IBD are more likely to be adherent to biologic therapies than other medications-authors' reply.
    Aliment Pharmacol Ther. 2020;51:916-917.
    PubMed    


  237. UNGAR B, Kopylov U
    Editorial: is vedolizumab effective for perianal Crohn's disease?
    Aliment Pharmacol Ther. 2020;51:912-913.
    PubMed    


  238. LOGAN M, Gkikas K, Svolos V, Nichols B, et al
    Analysis of 61 exclusive enteral nutrition formulas used in the management of active Crohn's disease-new insights into dietary disease triggers.
    Aliment Pharmacol Ther. 2020;51:935-947.
    PubMed     Abstract available


  239. ALRIC H, Amiot A, Kirchgesner J, Treton X, et al
    The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.
    Aliment Pharmacol Ther. 2020;51:948-957.
    PubMed     Abstract available


  240. UNGARO RC, Aggarwal S, Topaloglu O, Lee WJ, et al
    Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:831-842.
    PubMed     Abstract available


  241. CHEUNG KS, Chen L, Chan EW, Seto WK, et al
    Nonsteroidal anti-inflammatory drugs but not aspirin are associated with a lower risk of post-colonoscopy colorectal cancer.
    Aliment Pharmacol Ther. 2020;51:899-908.
    PubMed     Abstract available


    April 2020
  242. AL-ANI A, Prentice R, Rentsch C, Johnson D, et al
    Review Article: Prevention, Diagnosis and Management of COVID-19 in the Inflammatory Bowel Disease Patient.
    Aliment Pharmacol Ther. 2020 Apr 29. doi: 10.1111/apt.15779.
    PubMed     Abstract available


  243. KREIJNE JE, de Vries AC, de Veer RC, Bouma G, et al
    Limited added value of laboratory monitoring in thiopurine maintenance monotherapy in inflammatory bowel disease patients.
    Aliment Pharmacol Ther. 2020 Apr 28. doi: 10.1111/apt.15734.
    PubMed     Abstract available


  244. SALAMEH R, Kirchgesner J, Allez M, Carbonnel F, et al
    Long-term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids.
    Aliment Pharmacol Ther. 2020 Apr 28. doi: 10.1111/apt.15751.
    PubMed     Abstract available


  245. BIEMANS VBC, Savelkoul E, Gabriels RY, Simsek M, et al
    A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients.
    Aliment Pharmacol Ther. 2020 Apr 27. doi: 10.1111/apt.15730.
    PubMed     Abstract available


  246. DAUDE S, Remen T, Chateau T, Danese S, et al
    Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Apr 22. doi: 10.1111/apt.15739.
    PubMed     Abstract available


  247. LIU B, Wanders A, Wirdefeldt K, Sjolander A, et al
    Vagotomy and subsequent risk of inflammatory bowel disease: a nationwide register-based matched cohort study.
    Aliment Pharmacol Ther. 2020 Apr 22. doi: 10.1111/apt.15715.
    PubMed     Abstract available


  248. DULAI PS, Jairath V, Khanna R, Ma C, et al
    Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2020 Apr 21. doi: 10.1111/apt.15726.
    PubMed     Abstract available


  249. KOCHHAR GS, Desai A, Syed A, Grover A, et al
    Risk of de-novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medications.
    Aliment Pharmacol Ther. 2020 Apr 21. doi: 10.1111/apt.15721.
    PubMed     Abstract available


  250. AMIOT A, Filippi J, Abitbol V, Cadiot G, et al
    Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study.
    Aliment Pharmacol Ther. 2020 Apr 14. doi: 10.1111/apt.15717.
    PubMed     Abstract available


  251. LEE HH, Bae JM, Lee BI, Lee KM, et al
    Pregnancy outcomes in women with inflammatory bowel disease: A 10-year nationwide population-based cohort study.
    Aliment Pharmacol Ther. 2020 Apr 7. doi: 10.1111/apt.15654.
    PubMed     Abstract available


  252. BIEMANS VBC, Sleutjes JAM, de Vries AC, Bodelier AGL, et al
    Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
    Aliment Pharmacol Ther. 2020 Apr 1. doi: 10.1111/apt.15689.
    PubMed     Abstract available


  253. KING D, Reulen RC, Thomas T, Chandan JS, et al
    Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000-2018.
    Aliment Pharmacol Ther. 2020 Apr 1. doi: 10.1111/apt.15701.
    PubMed     Abstract available


  254. WILSON A, Peel C, Wang Q, Pananos AD, et al
    Letter: immunogenicity of infliximab-ready for routine prediction? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:813-814.
    PubMed    


  255. AMIOT A
    Letter: immunogenicity of infliximab-ready for routine prediction?
    Aliment Pharmacol Ther. 2020;51:812.
    PubMed    


  256. VERSTOCKT B, Ferrante M
    Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer?
    Aliment Pharmacol Ther. 2020;51:737-738.
    PubMed    


  257. DULAI PS
    Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:738-739.
    PubMed    


  258. CHAPUIS-BIRON C, Bourrier A, Nachury M, Nancey S, et al
    Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients.
    Aliment Pharmacol Ther. 2020;51:719-727.
    PubMed     Abstract available


    March 2020
  259. LAURIOT DIT PREVOST C, Azahaf M, Nachury M, Branche J, et al
    Bowel damage and disability in Crohn's disease: a prospective study in a tertiary referral centre of the Lemann Index and Inflammatory Bowel Disease Disability Index.
    Aliment Pharmacol Ther. 2020 Mar 27. doi: 10.1111/apt.15681.
    PubMed     Abstract available


  260. HUPE M, Riviere P, Nancey S, Roblin X, et al
    Compared efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study.
    Aliment Pharmacol Ther. 2020 Mar 22. doi: 10.1111/apt.15680.
    PubMed     Abstract available


  261. RODRIGUEZ-LAGO I, Castro-Poceiro J, Fernandez-Clotet A, Mesonero F, et al
    Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Mar 17. doi: 10.1111/apt.15687.
    PubMed     Abstract available


  262. PIOVANI D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, et al
    Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Mar 13. doi: 10.1111/apt.15692.
    PubMed     Abstract available


  263. MOURATIDOU N, Malmborg P, Sachs MC, Askling J, et al
    Adult height in patients with childhood-onset inflammatory bowel disease: a nationwide population-based cohort study.
    Aliment Pharmacol Ther. 2020 Mar 4. doi: 10.1111/apt.15667.
    PubMed     Abstract available


  264. BATTAT R
    Editorial: calcineurin inhibitors as a bridge to vedolizumab for severe ulcerative colitis.
    Aliment Pharmacol Ther. 2020;51:663-664.
    PubMed    


  265. WEI B, Wang J, Zhang Y, Zhao J, et al
    Letter: inflammatory bowel disease and risk of myocardial infarction.
    Aliment Pharmacol Ther. 2020;51:671-673.
    PubMed    


  266. SEBASTIAN S, Myers S
    Letter: infliximab induction regimens in steroid-refractory acute severe colitis-a propensity score analysis. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:666-667.
    PubMed    


  267. TANDON P, Huang V
    Letter: increased risk of caesarean section for women with IBD-more questions than answers. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:668-669.
    PubMed    


  268. SELINGER CP
    Letter: increased risk of caesarean section for women with IBD-more questions than answers.
    Aliment Pharmacol Ther. 2020;51:667-668.
    PubMed    


  269. AMIOT A
    Letter: new insights on tofacitinib dose de-escalation.
    Aliment Pharmacol Ther. 2020;51:578.
    PubMed    


  270. DULAI PS, Amiot A, Peyrin-Biroulet L, Jairath V, et al
    A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:553-564.
    PubMed     Abstract available


  271. LEE S, Seow CH, Adhikari K, Metcalfe A, et al
    Pregnant women with IBD are more likely to be adherent to biologic therapies than other medications.
    Aliment Pharmacol Ther. 2020;51:544-552.
    PubMed     Abstract available


    February 2020
  272. D'AMICO F, Bonovas S, Danese S, Peyrin-Biroulet L, et al
    Review article: faecal calprotectin and histologic remission in ulcerative colitis.
    Aliment Pharmacol Ther. 2020 Feb 12. doi: 10.1111/apt.15662.
    PubMed     Abstract available


  273. PAI RK, Jairath V, Feagan BG
    Editorial: histologic normalisation in ulcerative colitis.
    Aliment Pharmacol Ther. 2020;51:399-401.
    PubMed    


  274. CUSHING KC, Ananthakrishnan AN
    Editorial: histologic normalisation in ulcerative colitis. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:401.
    PubMed    


  275. MOCCIARO F, Scimeca D, Conte E, Bonaccorso A, et al
    Letter: the gap between guidelines and real clinical practice for dysplasia surveillance in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020;51:481-482.
    PubMed    


    January 2020
  276. SHAH ED, Coburn ES, Nayyar A, Lee KJ, et al
    Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.
    Aliment Pharmacol Ther. 2020 Jan 28. doi: 10.1111/apt.15637.
    PubMed     Abstract available


  277. GIBSON DJ, Ward MG, Rentsch C, Friedman AB, et al
    Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Jan 21. doi: 10.1111/apt.15643.
    PubMed     Abstract available


  278. TANDON P, Govardhanam V, Leung K, Maxwell C, et al
    Systematic review with meta-analysis: risk of adverse pregnancy-related outcomes in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Jan 7. doi: 10.1111/apt.15587.
    PubMed     Abstract available


  279. KAYAL M, Ungaro R
    Letter: is measurement of faecal biomarkers helpful for the early diagnosis and prediction of pouchitis after proctocolectomy for ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:190.
    PubMed    


  280. LAHARIE D, Riviere P
    Letter: should we intensify infliximab in acute severe ulcerative colitis?
    Aliment Pharmacol Ther. 2020;51:186-187.
    PubMed    


  281. SEBASTIAN S
    Letter: should we intensify infliximab in acute severe ulcerative colitis? Author's reply.
    Aliment Pharmacol Ther. 2020;51:188.
    PubMed    


  282. YAMAMOTO T, Shimoyama T, Kotze PG
    Letter: is measurement of faecal biomarkers helpful for the early diagnosis and prediction of pouchitis after proctocolectomy for ulcerative colitis?
    Aliment Pharmacol Ther. 2020;51:189-190.
    PubMed    


  283. PROBERT C
    Commentary: vitamin D supplementation in Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:201-202.
    PubMed    


  284. TOWNSEND T, Subramanian S
    Editorial: endoscopic inflammation in ileoanal pouches-does it really matter?
    Aliment Pharmacol Ther. 2020;51:170-171.
    PubMed    


  285. BENSON-POPE SJ, Gearry RB
    Editorial: better outcomes for Crohn's disease-more than just the drugs?
    Aliment Pharmacol Ther. 2020;51:167-168.
    PubMed    


  286. HART A
    Commentary: safety of anti-TNF use in pregnancy.
    Aliment Pharmacol Ther. 2020;51:205-206.
    PubMed    


  287. KAYAL M, Ungaro R
    Editorial: endoscopic inflammation in ileoanal pouches-does it really matter? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:172.
    PubMed    


  288. LUBER RP, Irving PM
    Editorial: establishing a joint approach to a common problem for gastroenterologists.
    Aliment Pharmacol Ther. 2020;51:306-307.
    PubMed    


  289. WINTER RW
    Editorial: effects of vedolizumab during pregnancy in the CONCEIVE study.
    Aliment Pharmacol Ther. 2020;51:307-308.
    PubMed    


  290. SHEN EX, Lord A, Doecke JD, Hanigan K, et al
    A validated risk stratification tool for detecting high-risk small bowel Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:281-290.
    PubMed     Abstract available


  291. CARD T, Ungaro R, Bhayat F, Blake A, et al
    Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data.
    Aliment Pharmacol Ther. 2020;51:149-157.
    PubMed     Abstract available


  292. GENIN M, Fumery M, Occelli F, Savoye G, et al
    Fine-scale geographical distribution and ecological risk factors for Crohn's disease in France (2007-2014).
    Aliment Pharmacol Ther. 2020;51:139-148.
    PubMed     Abstract available


    December 2019
  293. OLLECH JE, Dwadasi S, Rai V, Peleg N, et al
    Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Dec 25. doi: 10.1111/apt.15616.
    PubMed     Abstract available


  294. DONG C, Metzger M, Holsbo E, Perduca V, et al
    Systematic review with meta-analysis: mortality in acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Dec 10. doi: 10.1111/apt.15592.
    PubMed     Abstract available


    November 2019
  295. DULAI PS, Singh S, Jairath V, Ma C, et al
    Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Nov 22. doi: 10.1111/apt.15577.
    PubMed     Abstract available


  296. CUSHING KC, Tan W, Alpers DH, Deshpande V, et al
    Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission.
    Aliment Pharmacol Ther. 2019 Nov 7. doi: 10.1111/apt.15568.
    PubMed     Abstract available


  297. MOENS A, van der Woude CJ, Julsgaard M, Humblet E, et al
    Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.
    Aliment Pharmacol Ther. 2019 Nov 6. doi: 10.1111/apt.15539.
    PubMed     Abstract available


  298. SOH H, Im JP, Han K, Park S, et al
    Crohn's disease and ulcerative colitis are associated with different lipid profile disorders: a nationwide population-based study.
    Aliment Pharmacol Ther. 2019 Nov 6. doi: 10.1111/apt.15562.
    PubMed     Abstract available


  299. MENON S, Bressler B
    Editorial: aminosalicylates and nephrotoxicity-an issue put to rest.
    Aliment Pharmacol Ther. 2019;50:1059.
    PubMed    


    October 2019
  300. SANDS BE, Armuzzi A, Marshall JK, Lindsay JO, et al
    Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
    Aliment Pharmacol Ther. 2019 Oct 29. doi: 10.1111/apt.15555.
    PubMed     Abstract available


  301. PIOVANI D, Danese S, Peyrin-Biroulet L, Bonovas S, et al
    Inflammatory bowel disease: estimates from the global burden of disease 2017 study.
    Aliment Pharmacol Ther. 2019 Oct 29. doi: 10.1111/apt.15542.
    PubMed     Abstract available


  302. WILSON A, Peel C, Wang Q, Pananos AD, et al
    HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Oct 25. doi: 10.1111/apt.15563.
    PubMed     Abstract available


  303. VARKAS G, Ribbens C, Louis E, Van den Bosch F, et al
    Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies.
    Aliment Pharmacol Ther. 2019 Oct 25. doi: 10.1111/apt.15519.
    PubMed     Abstract available


  304. GUBATAN J, Chou ND, Nielsen OH, Moss AC, et al
    Systematic review with meta-analysis: association of vitamin D status with clinical outcomes in adult patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Oct 24. doi: 10.1111/apt.15506.
    PubMed     Abstract available


  305. LUU M, Benzenine E, Barkun A, Doret M, et al
    Safety of first year vaccination in children born to mothers with inflammatory bowel disease and exposed in utero to anti-TNFalpha agents: a French nationwide population-based cohort.
    Aliment Pharmacol Ther. 2019 Oct 15. doi: 10.1111/apt.15504.
    PubMed     Abstract available


  306. SANDBORN WJ, Panes J, Sands BE, Reinisch W, et al
    Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
    Aliment Pharmacol Ther. 2019 Oct 9. doi: 10.1111/apt.15514.
    PubMed     Abstract available


  307. SELINGER CP, Parkes GC, Bassi A, Limdi JK, et al
    Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patients.
    Aliment Pharmacol Ther. 2019 Oct 8. doi: 10.1111/apt.15497.
    PubMed     Abstract available


  308. LUND K, Larsen MD, Knudsen T, Kjeldsen J, et al
    The impact of anti-TNFalpha therapy on colectomy rates and corticosteroid treatment among 3001 paediatric and adolescent patients with ulcerative colitis-a nationwide study from 1995 to 2015.
    Aliment Pharmacol Ther. 2019 Oct 3. doi: 10.1111/apt.15510.
    PubMed     Abstract available


  309. DAI C, Jiang M, Sun MJ
    Letter: increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFalpha agents, particularly etanercept, for autoimmune diseases other than IBD.
    Aliment Pharmacol Ther. 2019;50:834-835.
    PubMed    


  310. DOLINGER MT, Rolfes P, Phan BL, Dubinsky MC, et al
    Letter: tofacitinib use for biologic-refractory paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019;50:966-967.
    PubMed    


  311. LIN YS, Chen MJ, Lin WC, Wang YH, et al
    Letter: should we delay surgery, or stop anti-TNF therapy prior to elective surgical procedures in Crohn's disease patients receiving anti-TNF agents? Authors' reply.
    Aliment Pharmacol Ther. 2019;50:970-971.
    PubMed    


  312. YAMAMOTO T, Kotze PG
    Letter: should we delay surgery, or stop anti-TNF therapy prior to elective surgical procedures in Crohn's disease patients receiving anti-TNF agents?
    Aliment Pharmacol Ther. 2019;50:969-970.
    PubMed    


  313. WALL CL, Day AS
    Editorial: the reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food reintroduction.
    Aliment Pharmacol Ther. 2019;50:824-825.
    PubMed    


  314. ASHTON JJ, Beattie RM
    Letter: anti-TNF therapy and intestinal resections in Crohn's disease-are we just delaying the inevitable?
    Aliment Pharmacol Ther. 2019;50:842-843.
    PubMed    


  315. KORZENIK J, Larsen MD, Nielsen J, Kjeldsen J, et al
    Editorial: anti-TNF therapy-a double-edged sword? Authors' reply.
    Aliment Pharmacol Ther. 2019;50:823-824.
    PubMed    


  316. SCHREINER P, Biedermann L
    Editorial: anti-TNF therapy-a double-edged sword?
    Aliment Pharmacol Ther. 2019;50:822-823.
    PubMed    


    September 2019
  317. ASHTON JJ, Latham K, Beattie RM, Ennis S, et al
    Review article: the genetics of the human leucocyte antigen region in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Sep 13. doi: 10.1111/apt.15485.
    PubMed     Abstract available


  318. IANNONE A, Ruospo M, Palmer SC, Principi M, et al
    Systematic review with network meta-analysis: endoscopic techniques for dysplasia surveillance in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Sep 9. doi: 10.1111/apt.15493.
    PubMed     Abstract available


  319. MOORE G
    Editorial: UK quality of care drive improving ulcerative colitis hospital outcomes.
    Aliment Pharmacol Ther. 2019;50:601-602.
    PubMed    


  320. BODGER K
    Editorial: UK quality of care drive improving ulcerative colitis hospital outcomes. Author's reply.
    Aliment Pharmacol Ther. 2019;50:602-603.
    PubMed    


  321. MCCURDY JD
    Letter: previous exposure to corticosteroids increases the risk of post-discharge venous thromboembolic events in patients with inflammatory bowel disease-author's reply.
    Aliment Pharmacol Ther. 2019;50:714-715.
    PubMed    


  322. ZENG J, Gan HT
    Letter: previous exposure to corticosteroids increases the risk of post-discharge venous thromboembolic events in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019;50:712-713.
    PubMed    


  323. FRASCA JD, Cheifetz AS
    Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry.
    Aliment Pharmacol Ther. 2019;50:599-600.
    PubMed    


  324. IBORRA M, Beltran B, Nos P
    Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:600-601.
    PubMed    


  325. DETLIE TE, Jahnsen J
    Editorial: awareness and prevention of intravenous iron-induced hypophosphataemia. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:610-611.
    PubMed    


  326. SEOW CH, Targownik LE
    Editorial: understanding sex and gender dimorphism in chronic diseases may improve outcomes.
    Aliment Pharmacol Ther. 2019;50:603-604.
    PubMed    


  327. MUSGROVE J, Wolf M
    Editorial: awareness and prevention of intravenous iron-induced hypophosphataemia.
    Aliment Pharmacol Ther. 2019;50:609-610.
    PubMed    


    August 2019
  328. CHOI YJ, Lee DH, Shin DW, Han KD, et al
    Patients with inflammatory bowel disease have an increased risk of myocardial infarction: a nationwide study.
    Aliment Pharmacol Ther. 2019 Aug 8. doi: 10.1111/apt.15446.
    PubMed     Abstract available


  329. BLACKWELL J, Saxena S, Alexakis C, Bottle A, et al
    The impact of smoking and smoking cessation on disease outcomes in ulcerative colitis: a nationwide population-based study.
    Aliment Pharmacol Ther. 2019 Aug 6. doi: 10.1111/apt.15390.
    PubMed     Abstract available


  330. CARMODY JK, Plevinsky J, Peugh JL, Denson LA, et al
    Longitudinal non-adherence predicts treatment escalation in paediatric ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Aug 2. doi: 10.1111/apt.15445.
    PubMed     Abstract available


  331. KREIJNE JE, de Veer RC, de Boer NK, Dijkstra G, et al
    Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment.
    Aliment Pharmacol Ther. 2019;50:407-415.
    PubMed     Abstract available


  332. LIN YS, Lin WC, Chen MJ, Wang YH, et al
    Letter: when to withhold anti-TNF agents prior to abdominal surgery in patients with Crohn's disease-the jury might still be out. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:465-466.
    PubMed    


  333. GATES R, Fogel S, Nguyen VQ, Sorrentino D, et al
    Letter: when to withhold anti-TNF agents prior to abdominal surgery in patients with Crohn's disease-the jury might still be out.
    Aliment Pharmacol Ther. 2019;50:464-465.
    PubMed    


  334. ISTL A, Yang ML, Fleshner KA, Parker CE, et al
    Letter: pre-operative anti-TNF therapy in Crohn's disease is not associated with increased complications following elective surgery.
    Aliment Pharmacol Ther. 2019;50:467-468.
    PubMed    


  335. LIN YS, Chen MJ, Lin WC, Wang YH, et al
    Letter: pre-operative anti-TNF therapy in Crohn's disease is not associated with increased complications following elective surgery. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:469-470.
    PubMed    


  336. PAUL S, Roblin X
    Letter: immunogenicity of anti-TNF in elderly IBD patients.
    Aliment Pharmacol Ther. 2019;50:336.
    PubMed    


  337. SINGH S, Jairath V
    Letter: immunogenicity of anti-TNF in elderly IBD patients-authors' reply.
    Aliment Pharmacol Ther. 2019;50:337.
    PubMed    


  338. GARBO GM, Renna S, Caputo V, Orlando E, et al
    Letter: psoriasiform eruption during vedolizumab therapy.
    Aliment Pharmacol Ther. 2019;50:342-343.
    PubMed    


    July 2019
  339. SCHULTHEISS JPD, Brand EC, Lamers E, van den Berg WCM, et al
    Earlier discontinuation of TNF-alpha inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects.
    Aliment Pharmacol Ther. 2019 Jul 16. doi: 10.1111/apt.15380.
    PubMed     Abstract available


  340. KORZENIK J, Larsen MD, Nielsen J, Kjeldsen J, et al
    Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFalpha agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Jul 2. doi: 10.1111/apt.15370.
    PubMed     Abstract available


  341. DETLIE TE, Lindstrom JC, Jahnsen ME, Finnes E, et al
    Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Aliment Pharmacol Ther. 2019 Jul 2. doi: 10.1111/apt.15386.
    PubMed     Abstract available


  342. BANERJEE T, Gearry R
    Editorial: suicide and IBD-a call to action.
    Aliment Pharmacol Ther. 2019;50:105-106.
    PubMed    


  343. BRYANT RV, Costello SP
    Editorial: assessing histological disease activity in Crohn's disease-a call for standardisation of mucosal biopsy location.
    Aliment Pharmacol Ther. 2019;50:103-104.
    PubMed    


  344. MALHAM M, Jakobsen C, Hald M, Paerregaard A, et al
    Editorial: suicide and IBD-a call to action. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:106-107.
    PubMed    


  345. VANDE CASTEELE N, Jairath V
    Editorial: assessing histological disease activity in Crohn's disease-a call for standardisation of mucosal biopsy location. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:104-105.
    PubMed    


    June 2019
  346. TEPLER A, Narula N, Peek RM Jr, Patel A, et al
    Systematic review with meta-analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Jun 5. doi: 10.1111/apt.15306.
    PubMed     Abstract available


  347. AMIOT A, Serrero M, Peyrin-Biroulet L, Filippi J, et al
    Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.
    Aliment Pharmacol Ther. 2019 Jun 5. doi: 10.1111/apt.15294.
    PubMed     Abstract available


  348. OLAISEN M, Fossmark R
    Editorial: mesalamine and mucosal microbiome in quiescent ulcerative colitis-what can we learn? Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1532.
    PubMed    


  349. BUCHNER AM, Lichtenstein GR
    Editorial: mesalazine and mucosal microbiome in quiescent ulcerative colitis-what can we learn?
    Aliment Pharmacol Ther. 2019;49:1531.
    PubMed    


  350. MURRAY CDR
    Editorial: combination immunosuppressive therapy to treat Crohn's disease - ready for all age groups?
    Aliment Pharmacol Ther. 2019;49:1528.
    PubMed    


  351. SINGH S, Jairath V, Lw S, G Z, et al
    Editorial: combination immunosuppressive therapy to treat Crohn's disease - ready for all age groups? Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1529.
    PubMed    


    May 2019
  352. SHAWIHDI M, Dodd S, Kallis C, Dixon P, et al
    Nationwide improvement in outcomes of emergency admission for ulcerative colitis in England, 2005-2013.
    Aliment Pharmacol Ther. 2019 May 28. doi: 10.1111/apt.15315.
    PubMed     Abstract available


  353. IANIRO G, Eusebi LH, Black CJ, Gasbarrini A, et al
    Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome.
    Aliment Pharmacol Ther. 2019 May 28. doi: 10.1111/apt.15330.
    PubMed     Abstract available


  354. MA C, Lee JK, Mitra AR, Teriaky A, et al
    Systematic review and meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 May 23. doi: 10.1111/apt.15297.
    PubMed     Abstract available


  355. MEYER A, Rudant J, Drouin J, Coste J, et al
    The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis in real-life.
    Aliment Pharmacol Ther. 2019 May 22. doi: 10.1111/apt.15323.
    PubMed     Abstract available


  356. MALHAM M, Jakobsen C, Paerregaard A, Virta LJ, et al
    The incidence of cancer and mortality in paediatric onset inflammatory bowel disease in Denmark and Finland during a 23-year period: a population-based study.
    Aliment Pharmacol Ther. 2019 May 8. doi: 10.1111/apt.15258.
    PubMed     Abstract available


  357. MCCURDY JD, Israel A, Hasan M, Weng R, et al
    A clinical predictive model for post-hospitalisation venous thromboembolism in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 May 8. doi: 10.1111/apt.15286.
    PubMed     Abstract available


  358. MURPHY B, O'Kane D, McCourt C
    Letter: paradoxical skin eruptions during anti-TNF-alpha treatment of Crohn's disease.
    Aliment Pharmacol Ther. 2019;49:1369-1370.
    PubMed    


    April 2019
  359. BOND A, Probert C
    Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1087-1088.
    PubMed    


  360. KESHTELI AH, Madsen KL, Mandal R, Boeckxstaens GE, et al
    Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1088-1089.
    PubMed    


  361. LEONG RWL, Kaakoush NO, Yau YY, Wasinger VC, et al
    Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission-confounded by the gut microbiome?
    Aliment Pharmacol Ther. 2019;49:1086-1087.
    PubMed    


  362. CHAN SSM
    Editorial: differences in sex-based incidence of inflammatory bowel diseases between Asia-Pacific and Western countries - are these due to differences in environment, access to healthcare, or pathophysiology?
    Aliment Pharmacol Ther. 2019;49:1098-1099.
    PubMed    


  363. VERSTOCKT B, Vermeire S, Ferrante M, Breynaert C, et al
    Editorial: biomarker predictors of non-response to TNFalpha antagonists - the quest continues. Authors' reply.
    Aliment Pharmacol Ther. 2019;49:1091-1092.
    PubMed    


  364. SHOUVAL DS, Ben-Horin S
    Editorial: biomarker predictors of non-response to TNFalpha antagonists-the quest continues.
    Aliment Pharmacol Ther. 2019;49:1089-1090.
    PubMed    


  365. LIN YS, Cheng SW, Wang YH, Chen KH, et al
    Systematic review with meta-analysis: risk of post-operative complications associated with pre-operative exposure to anti-tumour necrosis factor agents for Crohn's disease.
    Aliment Pharmacol Ther. 2019;49:966-977.
    PubMed     Abstract available


  366. CASTIGLIONE F, Imperatore N, Testa A, De Palma GD, et al
    One-year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing.
    Aliment Pharmacol Ther. 2019;49:1026-1039.
    PubMed     Abstract available


  367. CATT H, Hughes D, Kirkham JJ, Bodger K, et al
    Systematic review: outcomes and adverse events from randomised trials in Crohn's disease.
    Aliment Pharmacol Ther. 2019;49:978-996.
    PubMed     Abstract available


  368. ADAR T, Faleck D, Sasidharan S, Cushing K, et al
    Comparative safety and effectiveness of tumor necrosis factor alpha antagonists and vedolizumab in elderly IBD patients: a multicentre study.
    Aliment Pharmacol Ther. 2019;49:873-879.
    PubMed     Abstract available


  369. SHAH SC, Khalili H, Chen CY, Ahn HS, et al
    Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific region.
    Aliment Pharmacol Ther. 2019;49:904-911.
    PubMed     Abstract available


    March 2019
  370. SIMSEK M, Lissenberg-Witte BI, van Riswijk MLM, Verschuren S, et al
    Off-label prescriptions of drugs used for the treatment of Crohn's disease or ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Mar 25. doi: 10.1111/apt.15229.
    PubMed     Abstract available


  371. OLAISEN M, Spigset O, Flatberg A, Granlund AVB, et al
    Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Mar 20. doi: 10.1111/apt.15227.
    PubMed     Abstract available


  372. JACKSON B, Begun J, Gray K, Churilov L, et al
    Clinical decision support improves quality of care in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Mar 7. doi: 10.1111/apt.15209.
    PubMed     Abstract available


  373. GIBSON DJ, Ward MG
    Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed.
    Aliment Pharmacol Ther. 2019;49:816-817.
    PubMed    


  374. BOUGUEN G, Siproudhis L
    Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy - early promise but more data needed. Authors' reply.
    Aliment Pharmacol Ther. 2019;49:817-818.
    PubMed    


  375. VERSTOCKT B, Verstockt S, Creyns B, Tops S, et al
    Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2019;49:572-581.
    PubMed     Abstract available


    February 2019
  376. BANK S, Julsgaard M, Abed OK, Burisch J, et al
    Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Feb 27. doi: 10.1111/apt.15187.
    PubMed     Abstract available


  377. DROBNE D, Kurent T, Golob S, Svegl P, et al
    Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Feb 19. doi: 10.1111/apt.15179.
    PubMed     Abstract available


  378. SHIVAJI UN, Sharratt CL, Thomas T, Smith SCL, et al
    Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Feb 8. doi: 10.1111/apt.15097.
    PubMed     Abstract available


  379. SHAH A, Morrison M, Burger D, Martin N, et al
    Systematic review and meta-analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Feb 8. doi: 10.1111/apt.15133.
    PubMed     Abstract available


  380. CHEN P, Li Y, Li L, Yu Q, et al
    Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Feb 7. doi: 10.1111/apt.15159.
    PubMed     Abstract available


  381. DE FRANCISCO R, Castano-Garcia A, Riestra S
    Letter: impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2019;49:477-478.
    PubMed    


  382. AHMED T, Brown F, Ahmed R, Shah A, et al
    Letter: impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019;49:476-477.
    PubMed    


  383. DING R, Xu J, He Z, Chen Y, et al
    Letter: different risks of venous thromboembolism in subsets of patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2019;49:345-346.
    PubMed    


  384. CHU TPC, Grainge MJ, Card TR
    Letter: different risks of venous thromboembolism in subsets of patients with inflammatory bowel diseases - authors' reply.
    Aliment Pharmacol Ther. 2019;49:346.
    PubMed    


  385. PANES J, D'Haens GR, Higgins PDR, Mele L, et al
    Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study.
    Aliment Pharmacol Ther. 2019;49:265-276.
    PubMed     Abstract available


  386. LAI CY, Sung J, Cheng F, Tang W, et al
    Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation.
    Aliment Pharmacol Ther. 2019;49:354-363.
    PubMed     Abstract available


    January 2019
  387. KESHTELI AH, Madsen KL, Mandal R, Boeckxstaens GE, et al
    Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers.
    Aliment Pharmacol Ther. 2019 Jan 31. doi: 10.1111/apt.15141.
    PubMed     Abstract available


  388. GHERSIN I, Khteeb N, Katz LH, Daher S, et al
    Trends in the epidemiology of inflammatory bowel disease among Jewish Israeli adolescents: a population-based study.
    Aliment Pharmacol Ther. 2019 Jan 27. doi: 10.1111/apt.15160.
    PubMed     Abstract available


  389. OSTERMAN MT, Rosario M, Lasch K, Barocas M, et al
    Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation.
    Aliment Pharmacol Ther. 2019 Jan 20. doi: 10.1111/apt.15113.
    PubMed     Abstract available


  390. AGRAWAL M, Cohen-Mekelburg S, Kayal M, Axelrad J, et al
    Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors.
    Aliment Pharmacol Ther. 2019 Jan 20. doi: 10.1111/apt.15107.
    PubMed     Abstract available


  391. CHAPARRO M, Garre A, Ricart E, Iglesias-Flores E, et al
    Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU.
    Aliment Pharmacol Ther. 2019 Jan 13. doi: 10.1111/apt.15114.
    PubMed     Abstract available


  392. ASHTON JJ, Borca F, Mossotto E, Coelho T, et al
    Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood.
    Aliment Pharmacol Ther. 2019 Jan 9. doi: 10.1111/apt.15094.
    PubMed     Abstract available


  393. LUCIDARME C, Petitcollin A, Brochard C, Siproudhis L, et al
    Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.
    Aliment Pharmacol Ther. 2019;49:147-154.
    PubMed     Abstract available


  394. MACALUSO FS, Cappello M, Giuffrida E, Fries W, et al
    Letter: SPOSIB SB2-a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2.
    Aliment Pharmacol Ther. 2019;49:234-236.
    PubMed    


  395. LEMBERG DA, Day AS
    Editorial: predicting response to treatment in children with Crohn's disease.
    Aliment Pharmacol Ther. 2019;49:230-231.
    PubMed    


  396. HYAMS JS, Dubinsky M, Rosh J, Ruemmele FM, et al
    The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis.
    Aliment Pharmacol Ther. 2019;49:155-164.
    PubMed     Abstract available


  397. HALMOS EP, Mack A, Gibson PR
    Review article: emulsifiers in the food supply and implications for gastrointestinal disease.
    Aliment Pharmacol Ther. 2019;49:41-50.
    PubMed     Abstract available


    December 2018
  398. MA C, Guizzetti L, Cipriano LE, Parker CE, et al
    Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies.
    Aliment Pharmacol Ther. 2018 Dec 19. doi: 10.1111/apt.15090.
    PubMed     Abstract available


  399. PARK SW, Kim TJ, Lee JY, Kim ER, et al
    Comorbid immune-mediated diseases in inflammatory bowel disease: a nation-wide population-based study.
    Aliment Pharmacol Ther. 2018 Dec 2. doi: 10.1111/apt.15076.
    PubMed     Abstract available


  400. KAMM MA
    Editorial: treating strictures in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48.
    PubMed    


  401. RIEDER F, Feagan BG, Jairath V
    Editorial: treating strictures in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2018;48.
    PubMed    


    November 2018
  402. SITTE J, Frentiu E, Baumann C, Rousseau H, et al
    Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: A prospective cohort study of methods for improving coverage.
    Aliment Pharmacol Ther. 2018 Nov 28. doi: 10.1111/apt.15057.
    PubMed     Abstract available


  403. NOURELDIN M, Higgins PDR, Govani SM, Cohen-Mekelburg S, et al
    Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids.
    Aliment Pharmacol Ther. 2018 Nov 14. doi: 10.1111/apt.15023.
    PubMed     Abstract available


  404. PUREWAL S, Chapman S, Czuber-Dochan W, Selinger C, et al
    Systematic review: the consequences of psychosocial effects of inflammatory bowel disease on patients' reproductive health.
    Aliment Pharmacol Ther. 2018 Nov 8. doi: 10.1111/apt.15019.
    PubMed     Abstract available


  405. ORFANOUDAKI E, Drygiannakis I, Koutroubakis IE
    Letter: is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator?
    Aliment Pharmacol Ther. 2018;48:1037-1038.
    PubMed    


  406. HANS AK, Scott FI
    Editorial: which inflammatory bowel disease patients should be screened for Epstein-Barr virus infection?
    Aliment Pharmacol Ther. 2018;48:1158-1159.
    PubMed    


  407. POTTER MD, Walker MM, Jones MP, Koloski NA, et al
    Letter: gluten sensitivity in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:1167-1168.
    PubMed    


  408. DE FRANCISCO R, Castano-Garcia A, Riestra S
    Editorial: which inflammatory bowel disease patients should be screened for Epstein-Barr virus infection? Authors' reply.
    Aliment Pharmacol Ther. 2018;48:1159-1160.
    PubMed    


  409. AL SULAIS E, AlAmeel T
    Letter: faecal calprotectin, clinical indices and the diagnosis of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:1166.
    PubMed    


    October 2018
  410. STEVENS TW, Matheeuwsen M, Lonnkvist MH, Parker CE, et al
    Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-Personalised medicine in its infancy.
    Aliment Pharmacol Ther. 2018 Oct 30. doi: 10.1111/apt.15033.
    PubMed     Abstract available


  411. PASCHOS P, Katsoula A, Salanti G, Giouleme O, et al
    Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life.
    Aliment Pharmacol Ther. 2018 Oct 30. doi: 10.1111/apt.15005.
    PubMed     Abstract available


  412. CHU TPC, Grainge MJ, Card TR
    The risk of venous thromboembolism during and after hospitalisation in patients with inflammatory bowel disease activity.
    Aliment Pharmacol Ther. 2018 Oct 8. doi: 10.1111/apt.15010.
    PubMed     Abstract available


  413. PHILPOTT H, Dougherty MK, Dellon ES
    Letter: screening for adrenal suppression in paediatric inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2018;48:885-886.
    PubMed    


  414. CHAPARRO M, Garre A, Ricart E, Iborra M, et al
    Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
    Aliment Pharmacol Ther. 2018;48:839-851.
    PubMed     Abstract available


  415. WOOD P, Henderson P
    Letter: screening for adrenal suppression in paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:884-885.
    PubMed    


    September 2018
  416. CANETE F, Manosa M, Clos A, Cabre E, et al
    Review article: the relationship between obesity, bariatric surgery, and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Sep 4. doi: 10.1111/apt.14956.
    PubMed     Abstract available


  417. STAPERSMA L, van den Brink G, Szigethy EM, Escher JC, et al
    Editorial: anxiety and depression in inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2018;48:687-688.
    PubMed    


  418. LEE HH, Bae JM, Lee BI
    Editorial: paradoxical skin lesions during anti-TNF treatment-an additional argument to consider new biologics as first-line therapy in inflammatory bowel disease. Authors' reply.
    Aliment Pharmacol Ther. 2018;48:684-685.
    PubMed    


  419. PARIENTE B, Blondeaux A
    Editorial: paradoxical skin lesions during anti-TNF treatment-an additional argument to consider new biologics as first line therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:683-684.
    PubMed    


  420. MIKOCKA-WALUS A, Knowles SR
    Editorial: anxiety and depression in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:686-687.
    PubMed    


  421. WEINBERG EM, Reddy KR
    Editorial: leave it unhooked? Possible benefits of ileostomy over ileal-pouch-anal anastomosis in patients with ulcerative colitis and primary sclerosing cholangitis in the setting of liver transplantation.
    Aliment Pharmacol Ther. 2018;48:581-582.
    PubMed    


    August 2018
  422. DE FRANCISCO R, Castano-Garcia A, Martinez-Gonzalez S, Perez-Martinez I, et al
    Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Aug 10. doi: 10.1111/apt.14933.
    PubMed     Abstract available


  423. GAGNIERE C, Bourrier A, Seksik P, Gornet JM, et al
    Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the GETAID.
    Aliment Pharmacol Ther. 2018 Aug 2. doi: 10.1111/apt.14926.
    PubMed     Abstract available


  424. SAVOYE G, Fumery M, Gower-Rousseau C
    Editorial: post-operative complications in elderly onset inflammatory bowel disease-what is surgery, what is disease, and what is delay of surgery? Authors' reply.
    Aliment Pharmacol Ther. 2018;48:384-385.
    PubMed    


  425. JULSGAARD M, Kjeldsen J, Brock B, Baumgart DC, et al
    Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:386-388.
    PubMed    


  426. MAHADEVAN U, Vermeire S, Lasch K, Abhyankar B, et al
    Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2018;48:388-389.
    PubMed    


  427. MYRELID P
    Editorial: post-operative complications in elderly onset inflammatory bowel disease-what is surgery, what is disease, and what is delay of surgery?
    Aliment Pharmacol Ther. 2018;48:383-384.
    PubMed    


  428. PEYRIN-BIROULET L, Lopez A, Cummings JRF, Dignass A, et al
    Review article: treating-to-target for inflammatory bowel disease-associated anaemia.
    Aliment Pharmacol Ther. 2018 Aug 1. doi: 10.1111/apt.14922.
    PubMed     Abstract available


  429. ERIKSSON C, Henriksson I, Brus O, Zhulina Y, et al
    Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population-based cohort study.
    Aliment Pharmacol Ther. 2018 Aug 1. doi: 10.1111/apt.14920.
    PubMed     Abstract available


    July 2018
  430. KOTZE PG, Ma C, Almutairdi A, Al-Darmaki A, et al
    Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jul 31. doi: 10.1111/apt.14919.
    PubMed     Abstract available


  431. JOOSSE ME, Aardoom MA, Kemos P, Turner D, et al
    Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN.
    Aliment Pharmacol Ther. 2018 Jul 8. doi: 10.1111/apt.14893.
    PubMed     Abstract available


  432. STAPERSMA L, van den Brink G, Szigethy EM, Escher JC, et al
    Systematic review with meta-analysis: anxiety and depression in children and adolescents with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jul 8. doi: 10.1111/apt.14865.
    PubMed     Abstract available


  433. ANSARI AR, Aziz A
    Editorial: an argument for low-dose thiopurine allopurinol combination use as first-line therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:97-98.
    PubMed    


  434. FRIEDMAN AB, Sparrow MP
    Editorial: an argument for low-dose thiopurine allopurinol combination use as first-line therapy in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2018;48:98-99.
    PubMed    


    June 2018
  435. HANLON I, Hewitt C, Bell K, Phillips A, et al
    Systematic review with meta-analysis: online psychological interventions for mental and physical health outcomes in gastrointestinal disorders including irritable bowel syndrome and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jun 14. doi: 10.1111/apt.14840.
    PubMed     Abstract available


  436. VAN DEN BRINK G, Stapersma L, Vlug LE, Rizopolous D, et al
    Clinical disease activity is associated with anxiety and depressive symptoms in adolescents and young adults with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jun 13. doi: 10.1111/apt.14832.
    PubMed     Abstract available


  437. PARK KT, Sceats L, Dehghan M, Trickey AW, et al
    Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jun 7. doi: 10.1111/apt.14842.
    PubMed     Abstract available


  438. GONCALVES J, Santos M, Acurcio R, Iria I, et al
    Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition.
    Aliment Pharmacol Ther. 2018 Jun 5. doi: 10.1111/apt.14808.
    PubMed     Abstract available


  439. BAE JM, Lee HH, Lee BI, Lee KM, et al
    Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Aliment Pharmacol Ther. 2018 Jun 5. doi: 10.1111/apt.14822.
    PubMed     Abstract available


  440. ALUKAIDEY S, Heerasing N
    Editorial: de novo inflammatory bowel disease following bariatric surgery-potential implications for research and clinical practice.
    Aliment Pharmacol Ther. 2018;47:1539-1540.
    PubMed    


  441. UNGARO R, Colombel JF
    Editorial: de novo inflammatory bowel disease following bariatric surgery-potential implications for research and clinical practice. Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1540.
    PubMed    


    May 2018
  442. TSE CS, Loftus EV Jr, Raffals LE, Gossard AA, et al
    Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 May 28. doi: 10.1111/apt.14829.
    PubMed     Abstract available


  443. SACLEUX SC, Sarter H, Fumery M, Charpentier C, et al
    Post-operative complications in elderly onset inflammatory bowel disease: a population-based study.
    Aliment Pharmacol Ther. 2018 May 8. doi: 10.1111/apt.14790.
    PubMed     Abstract available


  444. SEHGAL P, Colombel JF, Aboubakr A, Narula N, et al
    Systematic review: safety of mesalazine in ulcerative colitis.
    Aliment Pharmacol Ther. 2018 May 3. doi: 10.1111/apt.14688.
    PubMed     Abstract available


  445. FRAGAKI M, Karmiris K
    Editorial: monitoring vedolizumab trough serum concentration in inflammatory bowel disease-following the fate of anti-TNF-alpha agents?
    Aliment Pharmacol Ther. 2018;47:1323-1324.
    PubMed    


  446. PAVLIDIS P, Graham J, Gulati S, Dubois P, et al
    Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:1422-1423.
    PubMed    


  447. MANOSA M, Domenech E
    Letter: phenotype and natural history of elderly onset inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1421-1422.
    PubMed    


  448. CHRISTENSEN B, Gibson PR, Rubin DT
    Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1423-1424.
    PubMed    


  449. EVERHOV AH, Ludvigsson JF, Olen O
    Letter: phenotype and natural history of elderly onset inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:1420-1421.
    PubMed    


  450. PAPAMICHAEL K, Cheifetz AS
    Letter: infliximab concentrations during induction therapy-one size does not fit all.
    Aliment Pharmacol Ther. 2018;47:1334-1335.
    PubMed    


  451. MAK WY, Ng SC
    Editorial: ways to reduce emergency department utilisation among IBD patients.
    Aliment Pharmacol Ther. 2018;47:1325-1326.
    PubMed    


    April 2018
  452. MA C, Guizzetti L, Panaccione R, Fedorak RN, et al
    Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis.
    Aliment Pharmacol Ther. 2018 Apr 25. doi: 10.1111/apt.14672.
    PubMed     Abstract available


  453. WHITE JR, Phillips F, Monaghan T, Fateen W, et al
    Review article: novel oral-targeted therapies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Apr 19. doi: 10.1111/apt.14669.
    PubMed     Abstract available


  454. KURNOOL S, Nguyen NH, Proudfoot J, Dulai PS, et al
    High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2018 Apr 17. doi: 10.1111/apt.14665.
    PubMed     Abstract available


  455. MONINUOLA OO, Milligan W, Lochhead P, Khalili H, et al
    Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation.
    Aliment Pharmacol Ther. 2018 Apr 5. doi: 10.1111/apt.14606.
    PubMed     Abstract available


  456. TALEBAN S
    Editorial: older-onset inflammatory bowel disease-is it time to start looking beyond a number?
    Aliment Pharmacol Ther. 2018;47:1034-1035.
    PubMed    


  457. MAGRO F, Sousa HT
    Editorial: ulcerative colitis submucosal fibrosis and inflammation: more than just strictures.
    Aliment Pharmacol Ther. 2018;47:1033-1034.
    PubMed    


  458. LIM MH, Doecke JD, Radford-Smith GL
    Editorial: first among Equals-not for either infliximab or adalimumab in Crohn's disease-yet.
    Aliment Pharmacol Ther. 2018;47:1225-1226.
    PubMed    


  459. TEICH N, Bruns T, Stallmach A
    Letter: predicting azathioprine-associated pancreatitis in IBD-phenotype or genotype?
    Aliment Pharmacol Ther. 2018;47:1042-1043.
    PubMed    


  460. SPARROW MP
    Editorial: clinical trials in IBD-how much of a difference is enough?
    Aliment Pharmacol Ther. 2018;47:1032-1033.
    PubMed    


  461. MACALUSO FS, Orlando R, Renna S, Sapienza C, et al
    Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab.
    Aliment Pharmacol Ther. 2018;47:1040-1041.
    PubMed    


  462. STRIK AS, D'Haens GR
    Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1041-1042.
    PubMed    


  463. WILSON A, Jansen LE, Rose RV, Gregor JC, et al
    Letter: predicting azathioprine-associated pancreatitis in IBD-phenotype or genotype? Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1044-1045.
    PubMed    


    March 2018
  464. TANG MT, Keir ME, Erickson R, Stefanich EG, et al
    Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-beta7 integrin therapy for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Mar 30. doi: 10.1111/apt.14631.
    PubMed     Abstract available


  465. VOLLEBREGT PF, van Bodegraven AA, Markus-de Kwaadsteniet TML, van der Horst D, et al
    Impacts of perianal disease and faecal incontinence on quality of life and employment in 1092 patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Mar 9. doi: 10.1111/apt.14599.
    PubMed     Abstract available


  466. UNGARO R, Fausel R, Chang HL, Chang S, et al
    Bariatric surgery is associated with increased risk of new-onset inflammatory bowel disease: case series and national database study.
    Aliment Pharmacol Ther. 2018 Mar 7. doi: 10.1111/apt.14569.
    PubMed     Abstract available


  467. WALKER GJ, Moore L, Heerasing N, Hendy P, et al
    Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study.
    Aliment Pharmacol Ther. 2018 Mar 5. doi: 10.1111/apt.14563.
    PubMed     Abstract available


  468. LAHARIE D, Riviere P
    Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:689-690.
    PubMed    


  469. QIU XY, Lu MJ, Zhang HJ
    Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:690-691.
    PubMed    


  470. LOBATON T, De Vos M
    Editorial: infliximab trough levels and histological healing in ulcerative colitis-a step towards personalised biologic therapy.
    Aliment Pharmacol Ther. 2018;47:855-856.
    PubMed    


  471. DE SIMONE C
    Letter: what gastroenterologists should know about VSL#3.
    Aliment Pharmacol Ther. 2018;47:698-699.
    PubMed    


  472. WILS P, Bouhnik Y, Michetti P, Flourie B, et al
    Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.
    Aliment Pharmacol Ther. 2018;47:588-595.
    PubMed     Abstract available


  473. LIGHTNER AL, McKenna NP, Tse CS, Raffals LE, et al
    Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations.
    Aliment Pharmacol Ther. 2018;47:573-580.
    PubMed     Abstract available


  474. SINGH S, Andersen NN, Andersson M, Loftus EV Jr, et al
    Comparison of infliximab with adalimumab in 827 biologic-naive patients with Crohn's disease: a population-based Danish cohort study.
    Aliment Pharmacol Ther. 2018;47:596-604.
    PubMed     Abstract available


  475. VAN BODEGRAVEN AA, Boone NW
    Editorial: nocebo effect and switching to biosimilars.
    Aliment Pharmacol Ther. 2018;47:850-851.
    PubMed    


  476. PRATAP MOULI V, Kedia S, Ahuja V
    Letter: mucosal response in discriminating intestinal tuberculosis from Crohn's disease-when to look for it? Authors' reply.
    Aliment Pharmacol Ther. 2018;47:860-861.
    PubMed    


  477. SHARMA V, Mandavdhare HS, Dutta U
    Letter: mucosal response in discriminating intestinal tuberculosis from Crohn's disease-when to look for it?
    Aliment Pharmacol Ther. 2018;47:859-860.
    PubMed    


  478. BEN-HORIN S
    Editorial: restoring therapeutic infliximab drug levels in patients with loss of response-pharmacokinetics and anti-drug antibodies as useful guidance tools.
    Aliment Pharmacol Ther. 2018;47:845-846.
    PubMed    


    February 2018
  479. BARRE A, Colombel JF, Ungaro R
    Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Feb 12. doi: 10.1111/apt.14550.
    PubMed     Abstract available


  480. BALLOU S, Hirsch W, Singh P, Rangan V, et al
    Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014.
    Aliment Pharmacol Ther. 2018 Feb 7. doi: 10.1111/apt.14551.
    PubMed     Abstract available


  481. GORDON IO, Agrawal N, Willis E, Goldblum JR, et al
    Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation.
    Aliment Pharmacol Ther. 2018 Feb 6. doi: 10.1111/apt.14526.
    PubMed     Abstract available


  482. RIBALDONE DG, Saracco GM, Astegiano M, Pellicano R, et al
    Letter: therapeutic drug monitoring and inflammatory bowel disease-a call for an urgent standardization of the results.
    Aliment Pharmacol Ther. 2018;47:448-449.
    PubMed    


  483. COTE-DAIGNEAULT J, Luong ML, Colombel JF, Peerani F, et al
    Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti-TNF medications.
    Aliment Pharmacol Ther. 2018;47:446-447.
    PubMed    


  484. KHAN N, Lewis JD
    Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti-TNF medications-authors' reply.
    Aliment Pharmacol Ther. 2018;47:448.
    PubMed    


  485. PAPAMICHAEL K, Cheifetz AS
    Editorial: early post-induction anti-TNF drug monitoring can predict long-term therapeutic outcomes in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:436-437.
    PubMed    


  486. TSAI HH
    Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class?
    Aliment Pharmacol Ther. 2018;47:539-540.
    PubMed    


  487. BONOVAS S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, et al
    Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply.
    Aliment Pharmacol Ther. 2018;47:540-541.
    PubMed    


  488. BARCLAY ML, Stamp LK
    Editorial: vedolizumab as a treatment and cause of extra-intestinal manifestations of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:535-536.
    PubMed    


  489. PRIMAS C, Reinisch S, Novacek G
    Letter: addition of azathioprine to infliximab maintenance therapy in patients with anti-drug antibodies and subclinical inflammation.
    Aliment Pharmacol Ther. 2018;47:544-545.
    PubMed    


  490. TAO P, Wang SY
    Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated.
    Aliment Pharmacol Ther. 2018;47:443.
    PubMed    


  491. SABINO J, Torres J
    Editorial: the role of colonic inflammation in the progression of liver disease in patients with primary sclerosing cholangitis.
    Aliment Pharmacol Ther. 2018;47:439-440.
    PubMed    


  492. JALANKA J, Hillamaa A, Satokari R, Mattila E, et al
    The long-term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection.
    Aliment Pharmacol Ther. 2018;47:371-379.
    PubMed     Abstract available


  493. DREESEN E, Van Stappen T, Ballet V, Peeters M, et al
    Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.
    Aliment Pharmacol Ther. 2018;47:346-355.
    PubMed     Abstract available


    January 2018
  494. YACOUB W, Williet N, Pouillon L, Di-Bernado T, et al
    Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.
    Aliment Pharmacol Ther. 2018 Jan 31. doi: 10.1111/apt.14548.
    PubMed     Abstract available


  495. CHRISTENSEN B, Micic D, Gibson PR, Yarur A, et al
    Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.
    Aliment Pharmacol Ther. 2018 Jan 29. doi: 10.1111/apt.14525.
    PubMed     Abstract available


  496. MANOSA M, Calafat M, de Francisco R, Garcia C, et al
    Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study.
    Aliment Pharmacol Ther. 2018 Jan 25. doi: 10.1111/apt.14494.
    PubMed     Abstract available


  497. WALJEE AK, Liu B, Sauder K, Zhu J, et al
    Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis.
    Aliment Pharmacol Ther. 2018 Jan 22. doi: 10.1111/apt.14510.
    PubMed     Abstract available


  498. SWEENEY L, Moss-Morris R, Czuber-Dochan W, Meade L, et al
    Systematic review: psychosocial factors associated with pain in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jan 22. doi: 10.1111/apt.14493.
    PubMed     Abstract available


  499. OLIVERA P, Sandborn WJ, Panes J, Baumann C, et al
    Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey.
    Aliment Pharmacol Ther. 2018 Jan 19. doi: 10.1111/apt.14514.
    PubMed     Abstract available


  500. COLIZZO FP, Friedman LS
    Editorial: avoiding corticosteroids in the treatment of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:143-144.
    PubMed    


  501. BROEKMAN MMTJ, Wanten GJ, de Jong DJ
    Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageing. Authors' reply.
    Aliment Pharmacol Ther. 2018;47:130-131.
    PubMed    


  502. SELINGER CP, Parkes GC, Raine T
    Editorial: avoiding corticosteroids in the treatment of inflammatory bowel disease-Author's reply.
    Aliment Pharmacol Ther. 2018;47:145.
    PubMed    


  503. WILLINGTON AJ, Gearry RB
    Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageing.
    Aliment Pharmacol Ther. 2018;47:129-130.
    PubMed    


  504. MURRAY CD
    Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine.
    Aliment Pharmacol Ther. 2018;47:141-142.
    PubMed    


  505. MEIJER B, de Boer NKH
    Letter: thiopurines - is less really more?
    Aliment Pharmacol Ther. 2018;47:149.
    PubMed    


  506. DING NS, Malietzis G, Hart AL
    Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine. Authors' reply.
    Aliment Pharmacol Ther. 2018;47:142-143.
    PubMed    


  507. EBERHARDSON M, Soderling JK, Olen O
    Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? Authors' reply.
    Aliment Pharmacol Ther. 2018;47:147-148.
    PubMed    


  508. RIBALDONE DG, Saracco G, Astegiano M, Pellicano R, et al
    Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy?
    Aliment Pharmacol Ther. 2018;47:146-147.
    PubMed    


  509. LANG BM, Biedermann L, van Haaften WT, de Valliere C, et al
    Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2018;47:55-66.
    PubMed     Abstract available


  510. VANDE CASTEELE N, Feagan BG, Vermeire S, Yassine M, et al
    Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2018;47:229-237.
    PubMed     Abstract available


  511. BAR-YOSEPH H, Levhar N, Selinger L, Manor U, et al
    Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.
    Aliment Pharmacol Ther. 2018;47:212-218.
    PubMed     Abstract available


  512. NORDENVALL C, Olen O, Nilsson PJ, von Seth E, et al
    Colectomy prior to diagnosis of primary sclerosing cholangitis is associated with improved prognosis in a nationwide cohort study of 2594 PSC-IBD patients.
    Aliment Pharmacol Ther. 2018;47:238-245.
    PubMed     Abstract available


  513. ADAMS A, Kalla R, Satsangi J
    Editorial: the influence of genetic factors in mediating the effects of tobacco smoke in IBD.
    Aliment Pharmacol Ther. 2018;47:306-307.
    PubMed    


  514. SAWBRIDGE D, Subramanian S
    Editorial: the IBD-disability index-ready for prime time?
    Aliment Pharmacol Ther. 2018;47:298-299.
    PubMed    


  515. LANG BM, Beerenwinkel N, Misselwitz B
    Editorial: the influence of genetic factors in mediating the effects of tobacco smoke in IBD-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:307-308.
    PubMed    


    December 2017
  516. WILSON A, Jansen LE, Rose RV, Gregor JC, et al
    HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Dec 22. doi: 10.1111/apt.14483.
    PubMed     Abstract available


  517. TADBIRI S, Peyrin-Biroulet L, Serrero M, Filippi J, et al
    Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
    Aliment Pharmacol Ther. 2017 Dec 18. doi: 10.1111/apt.14419.
    PubMed     Abstract available


  518. PAPAMICHAEL K, Rakowsky S, Rivera C, Cheifetz AS, et al
    Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Dec 6. doi: 10.1111/apt.14458.
    PubMed     Abstract available


  519. SCHMITZ EMH, Boekema PJ, Straathof JWA, van Renswouw DC, et al
    Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.
    Aliment Pharmacol Ther. 2017 Dec 5. doi: 10.1111/apt.14453.
    PubMed     Abstract available


  520. LU MJ, Qiu XY, Mao XQ, Li XT, et al
    Systematic review with meta-analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Dec 4. doi: 10.1111/apt.14436.
    PubMed     Abstract available


  521. BONOVAS S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, et al
    Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Dec 4. doi: 10.1111/apt.14449.
    PubMed     Abstract available


  522. SINGH S, Fumery M, Sandborn WJ, Murad MH, et al
    Systematic review and network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Dec 4. doi: 10.1111/apt.14422.
    PubMed     Abstract available


  523. LOGAN M, Ijaz UZ, Hansen R, Gerasimidis K, et al
    Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease.
    Aliment Pharmacol Ther. 2017;46.
    PubMed    


  524. FEATHERS A, Swaminath A, Ananthakrishnan AN, Falzon L, et al
    Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2017;46.
    PubMed    


  525. DOMENECH E, Canete F, Manosa M
    Editorial: therapeutic drug monitoring for anti-TNF agents-has it all been said?
    Aliment Pharmacol Ther. 2017;46.
    PubMed    


  526. MARTINEAU C, Flourie B, Wils P, Vaysse T, et al
    Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study.
    Aliment Pharmacol Ther. 2017;46.
    PubMed     Abstract available


  527. MITREV N, Vande Casteele N, Seow CH, Andrews JM, et al
    Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;46.
    PubMed     Abstract available


    November 2017
  528. YU H, MacIsaac D, Wong JJ, Sellers ZM, et al
    Market share and costs of biologic therapies for inflammatory bowel disease in the USA.
    Aliment Pharmacol Ther. 2017 Nov 22. doi: 10.1111/apt.14430.
    PubMed     Abstract available


  529. COLOMBEL JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, et al
    Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Nov 21. doi: 10.1111/apt.14420.
    PubMed     Abstract available


  530. AYUBI E, Safiri S
    Letter: the outcome of ulcerative colitis patients undergoing pouch surgery may be determined by pre-surgical factors.
    Aliment Pharmacol Ther. 2017;46:901-902.
    PubMed    


  531. YANAI H, Ben-Shachar S, Mlynarsky L, Godny L, et al
    Letter: the outcome of ulcerative colitis patients undergoing pouch surgery may be determined by pre-surgical factors. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:902-903.
    PubMed    


  532. GOUYNOU C, Peyrin-Biroulet L
    Letter: addition of methotrexate neither restores clinical response nor improves the pharmacokinetic profile of vedolizumab-treated patients.
    Aliment Pharmacol Ther. 2017;46:1019-1020.
    PubMed    


  533. FEATHERS A, Swaminath A, Ananthakrishnan AN, Falzon L, et al
    Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2017;46:1026-1027.
    PubMed    


  534. DAI C, Cao Q, Jiang M
    Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:1025-1026.
    PubMed    


  535. FIORINO G, Correale C, Radice S, Allocca M, et al
    Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients.
    Aliment Pharmacol Ther. 2017;46:903-905.
    PubMed    


  536. ERIKSSON C, Cao Y, Rundquist S, Zhulina Y, et al
    Editorial: do thiopurines and biologics decrease the risk of colectomy? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:897-898.
    PubMed    


  537. KOMAKI Y, Yamada A, Komaki F, Sakuraba A, et al
    Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply.
    Aliment Pharmacol Ther. 2017;46:905-906.
    PubMed    


  538. H ALLIN K, Jess T
    Editorial: do thiopurines and biologics decrease the risk of colectomy?
    Aliment Pharmacol Ther. 2017;46:896-897.
    PubMed    


  539. NAKASE H, Motoya S, Matsumoto T, Watanabe K, et al
    Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
    Aliment Pharmacol Ther. 2017;46:873-882.
    PubMed     Abstract available


  540. DING NS, Malietzis G, Lung PFC, Penez L, et al
    The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm.
    Aliment Pharmacol Ther. 2017;46:883-891.
    PubMed     Abstract available


  541. CARDING SR, Davis N, Hoyles L
    Review article: the human intestinal virome in health and disease.
    Aliment Pharmacol Ther. 2017;46:800-815.
    PubMed     Abstract available


    October 2017
  542. KUMP P, Wurm P, Grochenig HP, Wenzl H, et al
    The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Oct 20. doi: 10.1111/apt.14387.
    PubMed     Abstract available


  543. MCILROY J, Ianiro G, Mukhopadhya I, Hansen R, et al
    Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management.
    Aliment Pharmacol Ther. 2017 Oct 16. doi: 10.1111/apt.14384.
    PubMed     Abstract available


  544. LO B, Prosberg MV, Gluud LL, Chan W, et al
    Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index.
    Aliment Pharmacol Ther. 2017 Oct 9. doi: 10.1111/apt.14373.
    PubMed     Abstract available


  545. SWAMINATH A, Feathers A, Ananthakrishnan AN, Falzon L, et al
    Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:645-656.
    PubMed     Abstract available


  546. ACTIS GC, Pellicano R
    Letter: Cuban immigrants to the US developing IBD have a progressive shortening of the lag between time of arrival and disease onset.
    Aliment Pharmacol Ther. 2017;46:768.
    PubMed    


  547. DAMAS O, Abreu MT
    Letter: Cuban immigrants to the US developing IBD have a progressive shortening of the lag between time of arrival and disease onset. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:768-769.
    PubMed    


  548. LUNG PFC, Ng SC
    Editorial: challenges in the development of a magnetic resonance imaging index for fistulising Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:696.
    PubMed    


    September 2017
  549. BERNSTEIN CN
    Review article: changes in the epidemiology of inflammatory bowel disease-clues for aetiology.
    Aliment Pharmacol Ther. 2017 Sep 26. doi: 10.1111/apt.14338.
    PubMed     Abstract available


  550. SELINGER CP, Parkes GC, Bassi A, Fogden E, et al
    A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Sep 26. doi: 10.1111/apt.14334.
    PubMed     Abstract available


  551. BROEKMAN MMTJ, Coenen MJH, Wanten GJ, van Marrewijk CJ, et al
    Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype.
    Aliment Pharmacol Ther. 2017 Sep 15. doi: 10.1111/apt.14323.
    PubMed     Abstract available


  552. XU L, Lochhead P, Ko Y, Claggett B, et al
    Systematic review with meta-analysis: breastfeeding and the risk of Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Sep 11. doi: 10.1111/apt.14291.
    PubMed     Abstract available


  553. ALEXAKIS C, Kumar S, Saxena S, Hotopf M, et al
    Editorial: depression in the setting of inflammatory bowel disease means we have failed to provide early, effective, psychosocial care-authors' reply.
    Aliment Pharmacol Ther. 2017;46:554-555.
    PubMed    


  554. KEEFER L
    Editorial: depression in the setting of inflammatory bowel disease means we have failed to provide early, effective, psychosocial care.
    Aliment Pharmacol Ther. 2017;46:553-554.
    PubMed    


  555. GRACIE DJ, Derwa Y, Hamlin PJ, Ford AC, et al
    Editorial: probiotics in inflammatory bowel disease-wrong organisms, wrong disease, or flawed concepts? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:633-634.
    PubMed    


  556. SHANAHAN F
    Editorial: probiotics in inflammatory bowel disease-wrong organisms, wrong disease, or flawed concepts?
    Aliment Pharmacol Ther. 2017;46:632-633.
    PubMed    


  557. LIM MH, Radford-Smith GL
    Editorial: faecal microbiota transplantation for ulcerative colitis-not quite there yet?
    Aliment Pharmacol Ther. 2017;46:630-631.
    PubMed    


  558. COSTELLO SP, Soo W, Bryant RV, Jairath V, et al
    Editorial: faecal microbiota transplantation for ulcerative colitis-not quite there yet? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:631-632.
    PubMed    


  559. EBERHARDSON M, Soderling JK, Neovius M, Cars T, et al
    Anti-TNF treatment in Crohn's disease and risk of bowel resection-a population based cohort study.
    Aliment Pharmacol Ther. 2017;46:589-598.
    PubMed     Abstract available


  560. SAMAAN MA, Puylaert CAJ, Levesque BG, Zou GY, et al
    The development of a magnetic resonance imaging index for fistulising Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:516-528.
    PubMed     Abstract available


  561. SPEIGHT RA, Mansfield JC
    Editorial: how effective is vedolizumab in the 'real world'?
    Aliment Pharmacol Ther. 2017;46:555-556.
    PubMed    


    August 2017
  562. ERIKSSON C, Cao Y, Rundquist S, Zhulina Y, et al
    Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Orebro, Sweden, 1963-2010.
    Aliment Pharmacol Ther. 2017 Aug 17. doi: 10.1111/apt.14268.
    PubMed     Abstract available


  563. KHAN N, Shah Y, Trivedi C, Lewis JD, et al
    Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications.
    Aliment Pharmacol Ther. 2017 Aug 14. doi: 10.1111/apt.14257.
    PubMed     Abstract available


  564. DAMAS OM, Schwartz SJ, Abreu MT
    Editorial: migration studies to determine risk and cause of inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2017;46:467.
    PubMed    


  565. KUENZIG ME, Benchimol EI
    Editorial: migration studies to determine risk and cause of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017;46:465-466.
    PubMed    


  566. WISKIN AE, Sandhu BK
    Editorial: changing nature of paediatric IBD-new insights from Irish data.
    Aliment Pharmacol Ther. 2017;46:457-458.
    PubMed    


  567. SEOW CH, Panaccione R
    Editorial: different tests for different drugs in Crohn's disease, or different tests for different people?
    Aliment Pharmacol Ther. 2017;46:463-464.
    PubMed    


  568. HUSSEY S
    Editorial: changing nature of paediatric IBD-new insights from Irish data. Author's reply.
    Aliment Pharmacol Ther. 2017;46:458-459.
    PubMed    


  569. WARD MG, Irving PM
    Editorial: different tests for different drugs in Crohn's disease, or different tests for different people? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:465.
    PubMed    


  570. WILLIAMS HRT, Orchard TR
    Editorial: volatile organic compounds in breath for monitoring IBD-longitudinal studies are essential.
    Aliment Pharmacol Ther. 2017;46:371-372.
    PubMed    


  571. SMOLINSKA A, van Schooten FJ
    Editorial: volatile organic compounds in breath for monitoring IBD-longitudinal studies are essential. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:372.
    PubMed    


    July 2017
  572. COATES MD, Tekin I, Vrana KE, Mawe GM, et al
    Review article: the many potential roles of intestinal serotonin (5-hydroxytryptamine, 5-HT) signalling in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Jul 24. doi: 10.1111/apt.14226.
    PubMed     Abstract available


  573. UNGARO RC, Colombel JF
    Editorial: biologics in inflammatory bowel disease-time for direct comparisons.
    Aliment Pharmacol Ther. 2017;46:68-69.
    PubMed    


  574. ANDREWS JM
    Editorial: yoga for QoL in ulcerative colitis-any better than other supportive activities?
    Aliment Pharmacol Ther. 2017;46:201-202.
    PubMed    


  575. CRAMER H, Dobos G, Langhorst J
    Editorial: yoga for QoL in ulcerative colitis-any better than other supportive activities? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:202-203.
    PubMed    


  576. VAN HAAFTEN WT, Mortensen JH, Karsdal MA, Bay-Jensen AC, et al
    Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:26-39.
    PubMed     Abstract available


  577. WARD MG, Warner B, Unsworth N, Chuah SW, et al
    Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.
    Aliment Pharmacol Ther. 2017;46:150-161.
    PubMed     Abstract available


  578. ANANTHAKRISHNAN AN, Sakuraba A, Barnes EL, Pekow J, et al
    The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:162-168.
    PubMed     Abstract available


  579. IMPERATORE N, Testa A, Caporaso N, Rispo A, et al
    Letter: anti-TNF dose de-escalation in Crohn's disease-a case-by-case decision.
    Aliment Pharmacol Ther. 2017;46:212.
    PubMed    


  580. AKSAN A, Isik H, Radeke HH, Dignass A, et al
    Editorial: which iron preparation for patients with IBD? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:195-196.
    PubMed    


  581. KENNEDY NA, Goodhand JR, Rampton DS
    Editorial: which iron preparation for patients with IBD?
    Aliment Pharmacol Ther. 2017;46:194-195.
    PubMed    


  582. PORTER CK, Riddle MS, Hooper TI
    Editorial: the Millennium study cohort-evaluating environmental determinates of IBD in the 21st Century. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:64-65.
    PubMed    


  583. KAPLAN GG
    Editorial: the Millennium study cohort-evaluating environmental determinates of IBD in the 21st century.
    Aliment Pharmacol Ther. 2017;46:63-64.
    PubMed    


  584. WANG S, Lin J
    Letter: determining the dominant role of environmental factors in UC development.
    Aliment Pharmacol Ther. 2017;46:77-78.
    PubMed    


    June 2017
  585. YANAI H, Ben-Shachar S, Mlynarsky L, Godny L, et al
    The outcome of ulcerative colitis patients undergoing pouch surgery is determined by pre-surgical factors.
    Aliment Pharmacol Ther. 2017 Jun 30. doi: 10.1111/apt.14205.
    PubMed     Abstract available


  586. DERWA Y, Gracie DJ, Hamlin PJ, Ford AC, et al
    Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Jun 27. doi: 10.1111/apt.14203.
    PubMed     Abstract available


  587. COSTELLO SP, Soo W, Bryant RV, Jairath V, et al
    Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Jun 14. doi: 10.1111/apt.14173.
    PubMed     Abstract available


  588. AMIOT A, Serrero M, Peyrin-Biroulet L, Filippi J, et al
    One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.
    Aliment Pharmacol Ther. 2017 Jun 8. doi: 10.1111/apt.14167.
    PubMed     Abstract available


  589. ALEXAKIS C, Kumar S, Saxena S, Pollok R, et al
    Systematic review and meta-analysis: the impact of a depressive state on disease course in adult inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Jun 2. doi: 10.1111/apt.14171.
    PubMed     Abstract available


  590. D'HAENS GR, Sandborn WJ, Zou G, Stitt LW, et al
    Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Jun 1. doi: 10.1111/apt.14164.
    PubMed     Abstract available


  591. STIDHAM RW, Waljee AK
    Editorial: visceral fat as a predictor of post-operative recurrence of Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:1551-1552.
    PubMed    


  592. COLLINS PD
    Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer.
    Aliment Pharmacol Ther. 2017;45:1553-1554.
    PubMed    


  593. HOLT DQ, Moore GT, Strauss BJG, Hamilton AL, et al
    Editorial: visceral fat as a predictor of post-operative recurrence of Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2017;45:1552-1553.
    PubMed    


  594. BONOVAS S, Fiorino G, Lytras T, Nikolopoulos G, et al
    Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer-authors' reply.
    Aliment Pharmacol Ther. 2017;45:1554-1555.
    PubMed    


  595. VANDE CASTEELE N, Gils A
    Editorial: variability in adalimumab trough and peak serum concentrations.
    Aliment Pharmacol Ther. 2017;45:1475-1476.
    PubMed    


  596. JAIRATH V, Feagan BG
    Editorial: the impact of the placebo effect in Crohn's disease - author's reply.
    Aliment Pharmacol Ther. 2017;45:1472.
    PubMed    


  597. BERNSTEIN CN
    Editorial: the impact of the placebo effect in Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:1471-1472.
    PubMed    


  598. WARD MG, Gibson PR, Sparrow MP
    Editorial: variability in adalimumab trough and peak serum concentrations - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1476-1477.
    PubMed    


    May 2017
  599. DAMAS OM, Avalos DJ, Palacio AM, Gomez L, et al
    Inflammatory bowel disease is presenting sooner after immigration in more recent US immigrants from Cuba.
    Aliment Pharmacol Ther. 2017 May 19. doi: 10.1111/apt.14145.
    PubMed     Abstract available


  600. NORTON C, Czuber-Dochan W, Artom M, Sweeney L, et al
    Systematic review: interventions for abdominal pain management in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 May 4. doi: 10.1111/apt.14108.
    PubMed     Abstract available


  601. CHRISTENSEN B, Sparrow MP
    Editorial: international consensus in clinical trial end-points in ulcerative colitis - clarity or just a step in clearing the fog?
    Aliment Pharmacol Ther. 2017;45:1274-1275.
    PubMed    


  602. LAMBA MJ, Tharayil VS, Gearry RB
    Editorial: inflammatory bowel disease risk reduction after migration - are early life events important?
    Aliment Pharmacol Ther. 2017;45:1367-1368.
    PubMed    


  603. NELSON A, Tsai HH
    Editorial: Clostridium difficile and inflammatory bowel disease - is it always a bad combination?
    Aliment Pharmacol Ther. 2017;45:1368-1369.
    PubMed    


  604. EVERHOV AH, Olen O, Ludvigsson JF
    Editorial: importance of definition of inflammatory bowel disease and an increased incidence in children.
    Aliment Pharmacol Ther. 2017;45:1369-1370.
    PubMed    


  605. HAWTHORNE AB
    Editorial: clinical benefits of vitamin D therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017;45:1365-1366.
    PubMed    


  606. MA C, Fedorak RN, Kaplan GG, Dieleman LA, et al
    Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.
    Aliment Pharmacol Ther. 2017;45:1232-1243.
    PubMed     Abstract available


  607. HOLT DQ, Moore GT, Strauss BJ, Hamilton AL, et al
    Visceral adiposity predicts post-operative Crohn's disease recurrence.
    Aliment Pharmacol Ther. 2017;45:1255-1264.
    PubMed     Abstract available


  608. KHORRAMI S, Gisbert JP
    Editorial: accumulating data about ustekinumab in refractory Crohn's disease in real world experience.
    Aliment Pharmacol Ther. 2017;45:1374-1375.
    PubMed    


  609. KOMAKI Y, Yamada A, Komaki F, Micic D, et al
    Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1372.
    PubMed    


  610. FELWICK R, Cummings JRF
    Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;45:1370-1371.
    PubMed    


  611. SHIM HH, Seow CH
    Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum?
    Aliment Pharmacol Ther. 2017;45:1283-1284.
    PubMed    


  612. MITREV N, Kariyawasam V, Leong RW
    Editorial: infliximab trough cut-off for perianal Crohn's disease - another piece of the therapeutic drug monitoring-guided infliximab dosing puzzle.
    Aliment Pharmacol Ther. 2017;45:1279-1280.
    PubMed    


  613. MAHADEVAN U, Vermeire S, Lasch K, Abhyankar B, et al
    Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Authors' reply.
    Aliment Pharmacol Ther. 2017;45:1284.
    PubMed    


    April 2017
  614. RODA G, Narula N, Pinotti R, Skamnelos A, et al
    Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14063.
    PubMed     Abstract available


  615. BYE WA, Jairath V, Travis SPL
    Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14075.
    PubMed     Abstract available


  616. ROBLIN X, Boschetti G, Williet N, Nancey S, et al
    Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14106.
    PubMed     Abstract available


  617. COUGHLAN A, Wylde R, Lafferty L, Quinn S, et al
    A rising incidence and poorer male outcomes characterise early onset paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14070.
    PubMed     Abstract available


  618. CRAMER H, Schafer M, Schols M, Kocke J, et al
    Randomised clinical trial: yoga vs written self-care advice for ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Apr 5. doi: 10.1111/apt.14062.
    PubMed     Abstract available


  619. JAIRATH V, Casteele NV, Hindryckx P
    Letter: dose optimising infliximab in acute severe ulcerative colitis - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1170-1171.
    PubMed    


  620. CHOY MC, De Cruz P
    Letter: dose optimising infliximab in acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017;45:1169-1170.
    PubMed    


  621. ANGELISON L, Marsal J, Hertervig E
    Letter: how to define remission in ulcerative colitis - histological remission should be considered. Authors' reply.
    Aliment Pharmacol Ther. 2017;45:1177-1178.
    PubMed    


  622. KILINCALP S, Ustun Y, Simsek Z
    Letter: how to define remission in ulcerative colitis - histological remission should be considered.
    Aliment Pharmacol Ther. 2017;45:1177.
    PubMed    


  623. YARUR AJ, Kanagala V, Stein DJ, Czul F, et al
    Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:933-940.
    PubMed     Abstract available


  624. VAN STEENBERGEN S, Bian S, Vermeire S, Van Assche G, et al
    Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study.
    Aliment Pharmacol Ther. 2017;45:923-932.
    PubMed     Abstract available


  625. ALLEN PB, Olivera P, Emery P, Moulin D, et al
    Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis.
    Aliment Pharmacol Ther. 2017;45:1058-1072.
    PubMed     Abstract available


  626. KOMAKI Y, Yamada A, Komaki F, Micic D, et al
    Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;45:1043-1057.
    PubMed     Abstract available


  627. WARD MG, Thwaites PA, Beswick L, Hogg J, et al
    Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:1135-1145.
    PubMed     Abstract available


  628. HAMMER T, Lophaven SN, Nielsen KR, von Euler-Chelpin M, et al
    Inflammatory bowel diseases in Faroese-born Danish residents and their offspring: further evidence of the dominant role of environmental factors in IBD development.
    Aliment Pharmacol Ther. 2017;45:1107-1114.
    PubMed     Abstract available


  629. JAIRATH V, Zou G, Parker CE, MacDonald JK, et al
    Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:1021-1042.
    PubMed     Abstract available


  630. ANANTHAKRISHNAN AN
    Editorial: co-existing immune-mediated disease in inflammatory bowel diseases - a new disease severity indicator? Author's reply.
    Aliment Pharmacol Ther. 2017;45:1168.
    PubMed    


  631. VEGH Z, Bessissow T, Afif W, Lakatos PL, et al
    Editorial: co-existing immune-mediated disease in inflammatory bowel diseases - a new disease severity indicator?
    Aliment Pharmacol Ther. 2017;45:1167.
    PubMed    


    March 2017
  632. CHOLAPRANEE A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, et al
    Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Aliment Pharmacol Ther. 2017 Mar 22. doi: 10.1111/apt.14030.
    PubMed     Abstract available


  633. AKSAN A, Isik H, Radeke HH, Dignass A, et al
    Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Mar 21. doi: 10.1111/apt.14043.
    PubMed     Abstract available


  634. SEOW CH, Leung Y, Vande Casteele N, Ehteshami Afshar E, et al
    The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Mar 20. doi: 10.1111/apt.14040.
    PubMed     Abstract available


  635. BONOVAS S, Fiorino G, Lytras T, Nikolopoulos G, et al
    Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Mar 6. doi: 10.1111/apt.14023.
    PubMed     Abstract available


  636. ARTOM M, Czuber-Dochan W, Norton C
    Letter: causes of fatigue in inflammatory bowel disease remain uncertain - authors' reply.
    Aliment Pharmacol Ther. 2017;45:763-764.
    PubMed    


  637. GRACIE DJ, Ford AC
    Letter: causes of fatigue in inflammatory bowel disease remain uncertain.
    Aliment Pharmacol Ther. 2017;45:762-763.
    PubMed    


  638. HEERASING N, Thompson B, Hendy P, Heap GA, et al
    Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:660-669.
    PubMed     Abstract available


  639. WINTER RW, Collins E, Cao B, Carrellas M, et al
    Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-alpha medications among patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;45:653-659.
    PubMed     Abstract available


  640. SEGAL JP, Ding NS, Worley G, Mclaughlin S, et al
    Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm.
    Aliment Pharmacol Ther. 2017;45:581-592.
    PubMed     Abstract available


  641. RADFORD-SMITH GL, Hartnell F, Doecke JD
    Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort - authors' reply.
    Aliment Pharmacol Ther. 2017;45:856-857.
    PubMed    


  642. YAMAMOTO T, Shimoyama T
    Letter: small bowel recurrence and fate of the rectum after total colectomy and ileostomy for Crohn's colitis.
    Aliment Pharmacol Ther. 2017;45:863.
    PubMed    


  643. FRASER AG
    Editorial: can we get more clinical benefit from thiopurine metabolite testing?
    Aliment Pharmacol Ther. 2017;45:857-858.
    PubMed    


  644. BARREIRO-DE ACOSTA M, Gisbert JP
    Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort.
    Aliment Pharmacol Ther. 2017;45:855-856.
    PubMed    


  645. WONG DR, Hooymans PM
    Editorial: can we get more clinical benefit from thiopurine metabolite testing? Authors' reply.
    Aliment Pharmacol Ther. 2017;45:858-859.
    PubMed    


  646. BEN-HORIN S, Ungar B, Roblin X
    Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors' reply.
    Aliment Pharmacol Ther. 2017;45:760-762.
    PubMed    


    February 2017
  647. SMOLINSKA A, Bodelier AG, Dallinga JW, Masclee AA, et al
    The potential of volatile organic compounds for the detection of active disease in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Feb 26. doi: 10.1111/apt.14004.
    PubMed     Abstract available


  648. STRIK AS, van den Brink GR, Ponsioen C, Mathot R, et al
    Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Feb 23. doi: 10.1111/apt.13994.
    PubMed     Abstract available


  649. PORTER CK, Welsh M, Riddle MS, Nieh C, et al
    Epidemiology of inflammatory bowel disease among participants of the Millennium Cohort: incidence, deployment-related risk factors, and antecedent episodes of infectious gastroenteritis.
    Aliment Pharmacol Ther. 2017 Feb 23. doi: 10.1111/apt.13991.
    PubMed     Abstract available


  650. LOPHAVEN SN, Lynge E, Burisch J
    The incidence of inflammatory bowel disease in Denmark 1980-2013: a nationwide cohort study.
    Aliment Pharmacol Ther. 2017 Feb 23. doi: 10.1111/apt.13971.
    PubMed     Abstract available


  651. LAW CC, Tariq R, Khanna S, Murthy S, et al
    Systematic review with meta-analysis: the impact of Clostridium difficile infection on the short and long-term risks of colectomy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Feb 16. doi: 10.1111/apt.13972.
    PubMed     Abstract available


  652. MAHADEVAN U, Vermeire S, Lasch K, Abhyankar B, et al
    Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Feb 7. doi: 10.1111/apt.13960.
    PubMed     Abstract available


  653. DOECKE JD, Hartnell F, Bampton P, Bell S, et al
    Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study.
    Aliment Pharmacol Ther. 2017;45:542-552.
    PubMed     Abstract available


  654. FUMERY M, Dulai PS, Meirick P, Farrell AM, et al
    Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy.
    Aliment Pharmacol Ther. 2017;45:381-390.
    PubMed     Abstract available


    January 2017
  655. DIEDEREN K, Hoekman DR, Leek A, Wolters VM, et al
    Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.
    Aliment Pharmacol Ther. 2017 Jan 31. doi: 10.1111/apt.13950.
    PubMed     Abstract available


  656. VUITTON L, Peyrin-Biroulet L, Colombel JF, Pariente B, et al
    Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.
    Aliment Pharmacol Ther. 2017 Jan 23. doi: 10.1111/apt.13948.
    PubMed     Abstract available


  657. HINDRYCKX P, Novak G, Vande Casteele N, Laukens D, et al
    Review article: dose optimisation of infliximab for acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Jan 11. doi: 10.1111/apt.13913.
    PubMed     Abstract available


  658. HARTERY K, O'Reilly S, Houlihan D, Doherty G, et al
    Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis.
    Aliment Pharmacol Ther. 2017;45:376-378.
    PubMed    


  659. HONG SN, Kim HJ, Kim KH, Han SJ, et al
    Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.
    Aliment Pharmacol Ther. 2017;45:253-263.
    PubMed     Abstract available


  660. GREGOIRE C, Lechanteur C, Briquet A, Baudoux E, et al
    Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;45:205-221.
    PubMed     Abstract available


  661. UNGAR B, Kopylov U, Engel T, Yavzori M, et al
    Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.
    Aliment Pharmacol Ther. 2017;45:276-282.
    PubMed     Abstract available


  662. PRATAP MOULI V, Munot K, Ananthakrishnan A, Kedia S, et al
    Endoscopic and clinical responses to anti-tubercular therapy can differentiate intestinal tuberculosis from Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:27-36.
    PubMed     Abstract available


  663. CHRISTENSEN B, Sparrow MP
    Editorial: adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:178-179.
    PubMed    


    December 2016
  664. ANGELISON L, Almer S, Eriksson A, Karling P, et al
    Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients.
    Aliment Pharmacol Ther. 2016 Dec 27. doi: 10.1111/apt.13893.
    PubMed     Abstract available


  665. CARRAT F, Seksik P, Colombel JF, Peyrin-Biroulet L, et al
    The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Dec 19. doi: 10.1111/apt.13897.
    PubMed     Abstract available


  666. WONG DR, Coenen MJ, Derijks LJ, Vermeulen SH, et al
    Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Dec 12. doi: 10.1111/apt.13879.
    PubMed     Abstract available


    November 2016
  667. KONIG J, Siebenhaar A, Hogenauer C, Arkkila P, et al
    Consensus report: faecal microbiota transfer - clinical applications and procedures.
    Aliment Pharmacol Ther. 2016 Nov 27. doi: 10.1111/apt.13868.
    PubMed     Abstract available


  668. ARTOM M, Czuber-Dochan W, Sturt J, Murrells T, et al
    The contribution of clinical and psychosocial factors to fatigue in 182 patients with inflammatory bowel disease: a cross-sectional study.
    Aliment Pharmacol Ther. 2016 Nov 20. doi: 10.1111/apt.13870.
    PubMed     Abstract available


  669. FEAGAN BG, Patel H, Colombel JF, Rubin DT, et al
    Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial.
    Aliment Pharmacol Ther. 2016 Nov 17. doi: 10.1111/apt.13852.
    PubMed     Abstract available


  670. AGGIO RB, White P, Jayasena H, de Lacy Costello B, et al
    Irritable bowel syndrome and active inflammatory bowel disease diagnosed by faecal gas analysis.
    Aliment Pharmacol Ther. 2016 Nov 10. doi: 10.1111/apt.13822.
    PubMed     Abstract available


  671. MAO EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, et al
    Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2016 Nov 10. doi: 10.1111/apt.13847.
    PubMed     Abstract available


  672. COLOMBEL JF, Jharap B, Sandborn WJ, Feagan B, et al
    Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
    Aliment Pharmacol Ther. 2016 Nov 7. doi: 10.1111/apt.13838.
    PubMed     Abstract available


    October 2016
  673. KIRCHGESNER J, Lemaitre M, Rudnichi A, Racine A, et al
    Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
    Aliment Pharmacol Ther. 2016 Oct 26. doi: 10.1111/apt.13835.
    PubMed     Abstract available


  674. SELINGER CP, Carbery I, Warren V, Rehman AF, et al
    The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Oct 25. doi: 10.1111/apt.13831.
    PubMed     Abstract available


  675. STALLMACH A, Langbein C, Atreya R, Bruns T, et al
    Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Aliment Pharmacol Ther. 2016 Oct 7. doi: 10.1111/apt.13813.
    PubMed     Abstract available


    September 2016
  676. D'HAENS G
    Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis.
    Aliment Pharmacol Ther. 2016 Sep 21. doi: 10.1111/apt.13803.
    PubMed     Abstract available


    May 2016
  677. BUISSON A, Vazeille E, Minet-Quinard R, Goutte M, et al
    Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2016;43:1069-79.
    PubMed     Abstract available


    April 2016
  678. KIRCHGESNER J, Sokol H
    Editorial: mongersen in Crohn's disease--a new contribution to the beginning of a long-awaited therapeutic revolution?
    Aliment Pharmacol Ther. 2016;43:838-9.
    PubMed    


  679. TORRES J, Bao X, Goel A, Colombel JF, et al
    The features of mucosa-associated microbiota in primary sclerosing cholangitis.
    Aliment Pharmacol Ther. 2016;43:790-801.
    PubMed     Abstract available


    March 2016
  680. TO N, Gracie DJ, Ford AC
    Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease.
    Aliment Pharmacol Ther. 2016;43:549-61.
    PubMed     Abstract available


  681. VEDAK P, Kroshinsky D, St John J, Xavier RJ, et al
    Genetic basis of TNF-alpha antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis.
    Aliment Pharmacol Ther. 2016;43:697-704.
    PubMed     Abstract available


  682. MONTELEONE G, Di Sabatino A, Ardizzone S, Pallone F, et al
    Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease.
    Aliment Pharmacol Ther. 2016;43:717-24.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: